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cis, cis Muconic acid (CCM) is a compound that can be chemically converted to adipic acid, a 
major component of several copolymer plastics. Biological CCM-producing pathways with high 
yields have been characterized in Escherichia coli; however the downstream extraction process 
is prohibitively expensive at an industrial scale. Saccharomyces cerevisiae is a better industrial 
production host for organic acids; however biological CCM-producing pathways in S. cerevisiae 
have been plagued with significantly lower yields as compared to production in E. coli. In this 
thesis CCM production was explored in S. cerevisiae by construction of a heterologous pathway 
expressing AroZ from K. pneumoniae, AroY from P. anserina and Hqd2 from C. albicans, which 
resulted in the production of 2.9 mg/L of CCM. Accumulation of a native metabolite, shikimate, 
was observed, implying inefficient channeling of carbon into the heterologous pathway. To test 
this hypothesis, the diversion of carbon flux into the heterologous pathway was explored by 
modulation of the pentafunctional Aro1 protein. Replacing the wild-type aro1 gene with a 
mutant version eliminated the accumulation of shikimate and increased the carbon flux into the 
heterologous pathway by 59%. In addition, two-step fermentations with aerobic and anaerobic 
phases were explored demonstrating the imbalance in oxygen requirements in the 
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1.1 Plastics and Chemical Synthesis 
 
Plastic is ubiquitously used in most facets of life such as cars, packaging, clothing and food to 
name a few. There are many different types of plastic such as polyvinylchloride, polystyrene, 
and nylon each with their own specific uses. The commonality in plastics is that they are mostly 
synthetic polymers of combinations of different monomeric building blocks. The variations in 
the chemistry of the building blocks lead to the different properties of plastic. These building 
blocks range from chlorinated compounds such as vinyl chloride, aromatics molecules such as 
styrene, amines and dicarboxylic acids. This study focuses on the di-carboxylic acids monomers, 
specifically cis,cis-muconic acid (CCM).  
cis,cis-Muconic acid is an unsaturated six carbon di-carboxylic acid1. It can be chemically 
hydrogenated to produce unsaturated adipic acid which is one of the most industrially relevant 
chemical building blocks today2. Adipic acid is on the list of the 50 top bulk chemicals produced 
with a worldwide production of nearly 3 million tonnes2. It is used in the production of nylons, 
lubricants, coatings for the chemical, pharmaceutical and food industries3,4. Adipic acid is 
presently manufactured from benzene, a carcinogenic derivative of the Benzene, Toluene and 
Xylene (BTX) fraction of petroleum5. Benzene is reduced at high temperatures and pressures to 
cyclohexane. Cyclohexane undergoes two oxidation steps under high pressure and temperature 
to yield a mixture of cyclohexanol and cyclohexanone. This mixture is further reacted in air and 
excess nitric acid and a copper or vanadium catalyst to produce adipic acid (Figure 1). This 
process is dependent on benzene and other petroleum derived feedstocks which are not 
limitless and have supply stability problems6. In the last five years the costs of a barrel of crude 
oil has varied from $120 to $507; this drastic price fluctuations can have significant impact of 
the production costs of plastics8. As the stability of oil production is further damaged by 
continuous conflict in oil producing countries, and by the inevitable depletion of the finite 



















Figure 1. Chemical synthesis of adipic acid. Benzene is reduced at pressure in the presence of a nickel 
catalyst to form cyclohexane. Cyclohexane is oxidized in the presence of a cobalt catalyst and high 
pressure and temperature to form a mixture of cyclohexanol and cyclohexanone. This mixture is further 





synthesis of adipic acid is also extremely energy intensive as the reactions need to be 
maintained under high pressure and temperature9. The nitric acid involved in the reduction of 
cyclohexanol and cyclohexanone to adipic acid is also extremely unsustainable. Nitric acid is 
made from ammonia, under high pressure and temperature making it an energy and cost 
intensive manufacturing process. It is estimated that around 10% of the world’s total nitric acid 
production is used in the synthesis of adipic acid10. As about 2% of the world’s energy 
production is used for the production of ammonia using the Haber process, it can be deduced 
that the production of adipic acid accounts for about 0.2% of the world’s entire energy 
production every year.  
Chemical production of adipic acid has negative environmental consequences as well. There is a 
large amount of NOx (NO2, N2O) emissions in the nitric acid assisted ring-opening step; life cycle 
analyses have shown that production of adipic acid is responsible for the production of nearly 
10% of the world’s anthropogenic production of  NOx gas11,12. NOx is a potent greenhouse gas 
and has a severe effect on global warming11. Production of adipic acid also uses benzene, a 
known carcinogen13 and produces NO2 which has been implicated in respiratory illnesses14. 
Thus, the chemical synthesis of adipic acid is not economically, energetically or environmentally 
sustainable by any metric. 
1.2 Biological Production of Muconic Acid 
 
In the past two decades, biological methods for producing fuels and chemicals have become 
mainstream and commercially feasible15. Metabolic engineering is the ability to modify and add 
to the genomes of microorganisms to allow them to produce novel, heterologous and 
industrially or medically relevant chemicals16,17. Biological engineering has been used to 
produce fuels18,19 , plastics such as polyhydroxyalkanoates (PHA), poly-3-hydroxybutyrates 
(PHBs) and polyethylene20,21, food additives22,23, pharmaceuticals24 and medicinal 
compounds25,26 and is taking over as alternative to large scale chemical production. As the 
feedstocks for microbial fermentation are renewably produced27–29 there are few supply 





˚C the process is not very energy intensive and there are very few toxic by-products. To 
continue to produce industrial scales of adipic acid, a biological production option is the most 
desirable way forward.  
1.2.1 Natural Microbial Production of Adipic and Muconic Acids 
 
The production of adipic acid via the biological degradation of cyclohexane and cyclohexanol 
has been reported in multiple bacterial strains such as Acinetobacter sp30 and Pseudomonas 
sp31. The degradation pathways of cyclohexanol and cyclohexanone include multiple 
characterized genes such as cyclohexanol dehydrogenases32 and monooxygenases33 and have 
been under investigation for quite some time. Addition of these heterologous gene clusters to 
E. coli supplemented with cyclohexanol and cyclohexanone have resulted in trace amounts of 
adipic acid produced30. However, given the fact that cyclohexanol is a petroleum-derived 
feedstock and the yield of adipic acid from its biological degradation is low it is not a feasible 
pursuit.  
Benzoate has also been used as a feedstock to produce biological adipic acid. This uses the 
bacterial β-ketoadipate pathway found in most species of soil bacteria such as Pseudomonas34, 
Burkholderia35 and Acinetobacter36. This pathway catalyzes the catabolism of benzoate into 
succinyl-coA and acetyl-coA via intermediates catechol and protocatechuic acid. Catechol is the 
branch-point in this pathway and can be subsequently cleaved by catechol-1,2-dioxygenase37 
into cis,cis-muconic acid (CCM). CCM can be chemically hydrogenated with a platinum catalyst 
to produce adipic acid38. Pseudomonas strains that have been grown under fed-batch 
conditions with supplemented benzoate produced CCM at a yield of 91%39. This process was 
further optimized by controlling oxygen supply resulting in high cell density fermentation that 
produced 44 g/L of CCM40. However, as benzene is toxic and inhibitory to cell growth at high 
concentrations and is a petroleum-derived feedstock, it is not the ideal production method to 
replace chemical synthesis of adipic acid. A direct conversion of glucose or similar renewable, 





1.2.2 The Chorismate Pathway 
 
Biological production of adipic acid using glucose as a starting substrate would require a native 
pathway that was capable of producing similar molecules. As benzene and cyclohexane are 
aromatic molecules, a cell’s native aromatic molecule producing pathway would be ideal to 
make precursors for the production of CCM. The most common aromatic producing pathway in 
microorganisms, both prokaryotic and eukaryotic, is the chorismate pathway41.  
The chorismate pathway is ubiquitous in most clades of life, however, its organization and 
structure is variable42. The basic chorismate pathway converts erythrose-4-phosphate (E4P) and 
phosphoenolpyruvate (PEP) into aromatic amino acids and molecules such as tyrosine and p-
aminobenzoic acid via several well characterized steps. The bacterial chorismate pathway is 
composed of multiple mono-functional enzymes that catalyze the conversion of E4P and PEP to 
chorismate with 3-dehydroshikimate (DHS) as an intermediate (Figure 2). All subsequent 
naming of the catalytic activities of the enzymes in this pathway will follow the bacterial system 
for convenience unless otherwise stated. The DAHP synthase activity catalyzed by AroF or AroG 
condenses E4P and PEP to produce 3-deoxy-D-arabino-heptulosonate 7-phosphate (DAHP). 
DAHP is cyclized to form 3-dehydroquinase (DHQ) by a 3-dehydroquinate synthase activity 
catalyzed by AroB. DHQ is subsequently converted to 3-dehydroshikimic acid (DHS) by a 3-
dehydroquinase encoded by AroD. DHS is reduced to form shikimic acid via the shikimate 
dehydrogenase AroE. Shikimate kinases, AroK and AroL, add a phosphate group to shikimic acid 
to produce shikimate-3-phosphate (S3P). S3P is converted into 5-enol-pyruvyl-shikimate-3-
phosphate (5-EPS) by 5-EPS synthase activity that is encoded by AroA43. 5-EPS is finally 
converted to chorismate by a chorismate synthase, AroC. Chorismate is then further converted 
into amino acids and vitamins by a multitude of enzymes. This organizational structure, with 
mostly distinct enzymes for each functionality, is also seen in plants, where the chorismate 











Figure 2. Diagram of chorismate pathway and heterologous production of cis, cis-muconic acid 
and associated native S. cerevisiae metabolism.  The native S. cerevisiae genes are labeled in 
black and the homologous E. coli genes are in blue. The heterologous genes indicating the 3-
dehydroshikimate dehydrogenase (aroZ) from K. pneumoniae, the protocatechuic acid 
decarboxlyase (aroY) also from K. pneumoniae and the catechol-dioxygenase (hqd2) from C. 
albicans are marked in green. The redox cofactors are marked in orange. The dashed lines 
represent allosteric feedback inhibition of Aro4 and Aro4 by tyrosine and phenylalanine, 
respectively. The underlined metabolites have been measured in this study. The green shading 
outlines the desired flow of carbon into the heterologous CCM pathway. The red shading outlines 
the native consumption of the pre-cursor DHS for aromatic molecule synthesis. The purple shading 





Compared to prokaryotes, where all the steps in the chorismate pathway are catalyzed by 
mono-functional enzymes, the steps from AroB to AroA are catalyzed by one pentafunctional 
polypeptide in eukaryotes42. In S. cerevisiae, this is the Aro1 polypeptide. Through phylogenetic 
analysis, it was observed that this is an ancient eukaryotic invention and is widespread in all 
lower eukaryotes and protozoans42. It has been proposed that the pentafunctional polypeptide 
probably arose through multiple gene fusions as its catalytic domains can be mapped by 
homology to the singular prokaryotic proteins45.  Interestingly, the chorismate pathway is 
completely absent from metazoans including humans; these organisms rely on acquiring 
aromatic molecules through their diet. 42  
The chorismate pathway is the gateway to produce all the aromatic molecules present in a cell 
ranging from amino acids, such as tyrosine, tryptophan and phenylalanine, to vitamins such as 
folates, and has also been demonstrated to produce heterologous secondary metabolites such 
as vanillin46 and styrene47. Thus, the chorismate pathway is central to cellular metabolism and is 
capable of shuttling large amounts of carbon. Modifying this pathway to produce industrial 
scales of CCM or adipic acid would appear to be a sensible choice.  
1.2.3 Heterologous Production of Muconic Acid in Escherichia coli 
 
The first semi-biological pathway to produce adipic acid from glucose (Figure 2) was engineered 
in Escherichia coli by K.M. Draths and J.W. Frost in 199448. The production of adipic acid was a 
two-step process in which cis,cis-muconic acid was produced at titers of 2.37 g/L via E.coli 
fermentation and extracted; subsequently the CCM was chemically reduced to produce adipic 
acid at a 90% efficiency. This E. coli strain did not natively produce CCM and was rationally 
engineered and complemented with heterologous enzymes. The native chorismate pathway 
used for aromatic amino acid biosynthesis was modulated to accumulate the precursor DHS 
which was then converted to CCM via three heterologous proteins. Upon optimization of 
central carbon-metabolism and the chorismate pathway, CCM titers of 36.8 g/L were achieved9. 
The optimization of CCM production was achieved through multiple pathway modifications. 





studied43,49,50. This pathway uses PEP and E4P from glycolysis and the pentose phosphate 
pathway and condenses them to form DAHP. This marks the first committed step in the 
chorismate pathway and is catalyzed by 3 isozymes, the major one being AroF in 
prokaryotes43,48. AroF and its isozymes are feedback inhibited by tyrosine and phenylalanine 
limiting the carbon flux into the pathway. Niu et al. overcame this inhibition by over-expressing 
a copy of feedback inhibition resistant AroFfbr 51,52 on a plasmid and disrupting the native aroF 
promoter53,52. Increasing the flux though the chorismate pathway by eliminating feedback 
inhibition resulted in the accumulation of DAHP which was alleviated by expressing a second 
copy of the native aroB gene encoding a 3-dehydroquinqte synthase52. To accumulate 3-
dehydroshikimic acid the aroE gene encoding shikimate dehydrogenase, which converts DHS to 
shikimic acid, was deleted. The resulting strain, although accumulating large amounts of DHS, 
was unable to produce aromatic molecules and its growth media needed to be supplemented 
with the aromatic amino acids and vitamins52. The accumulated DHS was converted to 
protocatechuic acid by expression of 2 copies of heterologous aroZ gene from Klebsiella 
pneumoniae encoding a DHS dehydratase (DHSD). Protocatechuic acid (PCA) was subsequently 
decarboxylated to catechol by a heterologous PCA decarboxylase (PCAD) aroY, also from K. 
pneumoniae. Catechol finally underwent a ring-opening catalyzed by catechol-1,2-dioxygenase 
(CDO) expressed by the catA gene from Acinetobactor calcoaceticus resulting in 17 g/L of CCM. 
To improve yields the pentose phosphate pathway was up-regulated by expressing multiple 
copies of the native transketolase TktA50. Additionally, an extra copy of catA was maintained on 
a plasmid creating a CCM overproducing strain. This strain was grown under high oxygen 
fermentation to finally yield 36.8 g/L of CCM.  The clarified broth containing CCM was 
hydrogenated under high pressure hydrogen gas and a platinum catalyst to produce adipic acid 
at 97% efficiency38.  
Recently, three other routes to CCM have been discerned and demonstrated in E.coli, all 
derived from the chorismate pathway. In 2013, Sun et al. demonstrated a novel biosynthesis 
pathway for CCM production via the tryptophan precursor anthranilate54. Anthranilate is 
derived from the chorismate pathway and is the first intermediate in tryptophan bio-





catechol which is subsequently converted into cis,cis-muconic acid via a catechol-1,2-
dioxygenase (CDO). Multiple ADO’s and CDO’s were screened in vivo and the ADO, PaantABC, 
from Podospora aeruginosa and the CDO, CatA, from Podospora putida were chosen. Upon up-
regulation of carbon flux through the chorismate pathway by alleviating feedback-inhibition, as 
previously mentioned9, 389.96 mg/L of CCM was produced in a 32-hr fermentation in shake-
flasks.  
A year later, in 2014, the same group reported another novel CCM biosynthetic route 55. In this 
route, chorismate was shunted to isochorismate via an isochorismate synthase (ICS)56. 
Isochromate was then converted to salicyclic acid (SA) via an isochromate pyruvate lyase (IPL)57. 
A salicyclate-1-monoxygenase (SMO) catalyzed the conversion of salicyclic acid to catechol, 
which was finally converted to CCM via a CDO. In order to increase the availability of 
chorismate, pheA and tyrA, genes encoding proteins that funnel chorismate into phenylalanine 
and tyrosine biosynthesis, were deleted. Coupled with overexpression of TktA, PpsA,  AroGfbr 58 
(an isozyme of AroF), EntC 58(an ICS from E. coli) and PchB58 (an IPL from Pseudomonas 
fluorescens) 1.2 g/L of SA was produced. Out of the multiple SMO’s screened in vivo, codon-
optimized NagH from P. putida was chosen as the best candidate to convert SA to catechol. 
Catechol was finally converted to CCM upon the addition of the catA gene54 from P. putida. 
After flux balancing through plasmid copy number optimization a strain producing 1.4 g/L of 
CCM was created. 
The isochorismate shunt from the chorismate pathway was also recently used by Wang et al. in 
2015 to create another novel CCM producing E. coli strain59. In this strain, isochorismate was 
converted to 2,3 dihydrobenzoic acid (2,3-DHB) by EntBA60 from K. pneumoniae. 2,3-DHB was 
converted to catechol by a 2,3-DHB decarboxylase, EntXp, also from K. pneumoniae60. Upon 
addition of CatA from P. putida and over-expression of the chorismate pathway 608 mg/L of 







1.2.4 Heterologous Production of Muconic Acid in Saccharomyces cerevisiae 
 
Even though these engineered E. coli strains produce large amounts of CCM, the process is very 
expensive for industrial scale-up. As E. coli grow and ferment under strictly neutral pH’s any 
organic acids that are produced are produced as salts. Extraction of the un-dissociated acids 
from the salts requires high levels of acidification of the broth and subsequent precipitation and 
desalting steps. A large amount of salt and calcium carbonate waste is produced in this step and 
is quite prohibitive at industrial scales. Additionally, E. coli fermentations and cultures are 
susceptible to phage contamination, which destroys the fermentation process and is extremely 
difficult to eradicate for subsequent fermentations. This adds a lot of cost and risk in the 
production process. In response to this, there is a recent trend in biological production to use a 
more robust organism such as Saccharomyces cerevisiae for industrial scale production.   
S. cerevisiae or Baker’s yeast is one of the best studied model organisms61. It is highly tractable 
with a large repertoire of genetic tools to add to, remove and modulate the functionality of the 
cells17. It is also generally regarded as safe and is highly resistant to viral infections62. Yeasts are 
also tolerant to multiple forms of chemical and fermentative inhibitors and have been 
demonstrated as robust and efficient microbial production hosts63–66. 
Weber et al. in 2012 demonstrated the proof of concept of the heterologous pathway 
developed by Niu et al. in S. cerevisiae67. Multiple homologs, both codon-optimized and un-
optimized, for each of the heterologous steps were screened via in vivo testing. Through this 
analysis, the DHSD expressed by codon-optimized aroZ gene from Podospora anserina (also 
known as P. pauciseta), the PCAD encoded by the codon-optimized aroY gene from K. 
pneumonia and the CDO expressed by catA from Acinetobacter radioresistens were chosen. In 
order to accumulate DHS, the native chorismate pathway was modified in a way similar to what 
Niu et al. did in E. coli with the deletion of aroE. In E. coli and most other prokaryotes the seven 
chorismate pathway reactions are catalyzed by seven distinct enzymes and the deletion of any 
of the enzymes leads to the accumulation of its substrate43. Thus, the deletion of aroE, which 





eukaryotes, specifically S. cerevisiae, the seven enzymatic steps of the chorismate pathway are 
catalyzed by only three enzymes41. Aro4 and its paralog Aro3 condense E4P and PEP to produce 
DAHP. The next five steps from DAHP to 5-enolpyruvyl shikimate-3-phosphate (5-ESP) are 
catalyzed by a single protein Aro1. Aro2 catalyzes the conversion of 5-ESP to chorismate. The 
Aro1 protein is a pentafuntional protein with 5 different active sites all fused into one protein68. 
The five distinct chorismate forming enzymes in E. coli can be aligned using homology to the 
Aro1 protein. The shikimate dehydrogenase domain responsible for catalyzing the conversion 
of DHS to shikimic acid is located at the 3’ or N-terminal of Aro168. Weber et al. replaced the 
entire domain with a stop codon, effectively removing shikimate dehydrogenase activity from 
Aro167. With this modification and the expression of the screened heterologous enzymes 1.56 
mg/L of CCM was produced. This titer is considerably lower than the 36.8 g/L of CCM as 
reported by Niu et al. in E. coli. However, Weber et al. did not alleviate the feedback inhibition 
in the chorismate pathway and there was no attempt at flux balancing to improve metabolite 
conversion in the strains.   
The optimization of this pathway in S. cerevisiae was performed by Curran et al. in 201369. 
Multiple codon-optimized and non-codon optimized enzymes for all three of the heterologous 
activities were tested in vivo. Finally, a DHSD, aroZ, from P. anserina; a PCAD, ecl_01944, from 
Enterobacter cloacae and a CDO, hqd2, from Candida albicans were selected to construct the 
CCM pathway. Curran et al. alleviated the feedback inhibition in the chorismate pathway by 
deregulating the endogenous DAHP synthase activity by deleting the aro3 and aro4 genes and 
over-expressing a chromosome-integrated copy of the feedback inhibition resistant mutant 
Aro4K229L as previously described by Luttick et al.  49. Expressing the heterologous enzymes in 
this aromatic pathway deregulated strain achieved a CCM titer of 21 mg/L. However, it was 
observed that there was a significant bottleneck in the heterologous pathway as there was an 
accumulation of 166 mg/L of PCA in this strain. This was addressed by expressing the PCAD on a 
high copy plasmid and integrating multiple copies of the PCAD using Ty2 retro-transposon δ 
elements found throughout the genome. The over-expression of the PCAD in conjunction with 
the over-expression of the other heterologous genes in a feedback inhibition resistant strain 





further optimize yields of CCM. In silico flux balance analysis has been widely used to identify 
(and eliminate) competing reactions and channel more carbon flux through the desired 
pathway70–74. An extant yeast genome model, iMM90475, was used and modified to include the 
three heterologous reactions. The model predicted a 60.9% mol/mol glucose yield of CCM on 
channeling carbon into the pentose phosphate pathway through the transketolase activity9,76 
instead of the oxidative branch of the pentose phosphate pathway which would result in the 
balance of availability of precursors E4P and PEP. It would also remove a major source of 
NADPH in the cell, which is required for the conversion of DHS to shikimate. In order to achieve 
this, Curran et al. deleted the glucose-6-phosphate dehydrogenase, zwf1, and over-expressed 
the native transketolase, Tlk1, on a high copy plasmid in the feedback inhibition resistant strain 
to create strain MU11. However, as the bottleneck of accumulating PCA was still present, 
multiple genomic integrations of PCAD were made in strain MU11 to create strain MU12 with a 
dramatically increased PCAD RNA transcript. Further over-expression of the DHSD, PCAD and 
CDO on high copy plasmids in strain MU12 resulted in a CCM titer of 77 mg/L with a yield of 3.9 
mg/g glucose. Finally, MU12 was grown on modified synthetic complete media with 40 g/L 
glucose for an extended period of 108 hrs. The final CCM titer in this strain was 141 mg/L, 
which represents an impressive 90-fold optimization over the strain reported by Weber et al.  
Recently, Horwitz et al. demonstrated the production of 2.7 g/L of PCA in a modified 
S.cerevisiae strain77.  This was done by deletion of the entire aro1 gene and replacing it with 
aroF, aroB, and aroD from E. coli to prevent the siphoning of DHS from the heterologous 
pathway. One copy of aroZ and five copies of aroY from K. pneumoniae and one copy of catA 
from C. albicans were integrated into the genome. As the deletion of aro1 resulted in the strain 
unable to produce any aromatic amino acids, 2-step fermentation was carried out to produce 
CCM. The cells were grown in YPD for 48hrs to accumulate biomass and subsequently washed 
and added to minimal media containing 40 g/L of the disaccharide sucrose. This two-step 
fermentation created a simple switch mechanism between a biomass-accumulation step in rich 
media and a production phase in minimal media. However, no catechol and CCM were 





integrated copies of the PCAD. Feeding the cells with 1 g/L of catechol resulted in the formation 
of unreported quantities of muconic acid.  
Thus, it can be ascertained that S. cerevisiae has the potential to become a microbial host for 
the industrial production of adipic acid via cis,cis-muconic acid. The best-characterized 
biosynthetic route to CCM stems from the native chorismate pathway and is dependent on the 
precursor DHS. Although strides have been made to up-regulate the carbon flux going through 
the pathway43,46,49 there is a still a roadblock to accumulation and availability of DHS. Weber et 
al. deleted the N-terminal domain of the pentafunctional Aro1 protein in an effort to disrupt 
the shikimate dehydrogenase catalytic function67. However, this did not make any discernible 
effect on the amount of PCA produced. However, when this truncated version of Aro1 was 
over-expressed on a plasmid the titer of PCA increased 7-fold. A similar result was also achieved 
by over-expressing E. coli AroB and AroD in E. coli pointing to the AroB and AroD functionalities 
to be limiting. Curran et al. did not modulate the flux though the Aro1. However, deletion of 
endogenous aro3 and aro4 genes and over-expressing Aro4fbr also accumulated 166 mg/L PCA. 
Thus alleviation of feedback inhibition and overexpression of AroB and AroD had similar effects 
on the amount of DHS being produced. From these data, we can conclude that there are 
several bottlenecks in the chorismate pathway and flux though the Aro1 protein is one of them.  
As described previously, given that most eukaryotes with the chorismate pathway have the 
pentafunctional Aro1 domain fusion it is possible there is an evolutionary reason for its 
persistence. Multiple enzymes could fuse together to increase the flux though the pathway by 
decreasing the need for diffusion of the substrates. 
1.3 Molecular Channeling and Co-localization 
 
1.3.1 Why is Metabolite Channeling and Enzyme Co-localization Important? 
 
Intracellular environments differ markedly from the dilute solutions in which most in vitro 
experiments are conducted78. Up to 30% of the cellular volume of E. coli is composed of 





diffusion and affects enzyme functionality79. This molecular crowding leads to inefficient 
distribution and diffusion of substrates and free-floating enzymes, accumulation of toxic 
intermediates and loss of substrates to competing pathways. Many cellular pathways overcome 
this through substrate channeling by utilizing multi-enzyme complexes and protein co-
localization80–82.  
Molecular channeling in natural systems is exemplified by tryptophan synthase, an α2β2 
complex83. It channels the metabolic intermediate indole from the active site of the α subunit 
to the active site of the β subunit. The subunits arrange themselves to form a hydrophobic 
intramolecular tunnel that connects the adjacent active sites and has a diameter matching that 
of four molecules of indole. A number of ligand-induced conformational changes channels the 
indole and prevents it from diffusing into the cytosolic bulk or accumulating, which effectively 
increases the reaction rates by two orders of magnitude over the free, un-complexed 
subunits84. Thus, a similar channeling mechanism could be the purpose of the pentafunctional 
Aro1 protein.  
1.3.2 Metabolite Channeling and Co-localization in Aro1 Homologs 
 
The metabolite-channeling hypothesis has been explored in the central chorismate pathway 
too. This hypothesis has been tested for the AroM enzyme in Aspergillus nidulans, which is a 
pentafunctional homolog of Aro1 from S. cerevisiae68. Over-expression of a DHSD at 15-17 
times its normal physiological levels led to an acute accumulation of PCA with a drastic 
reduction in the chorismate pathway intermediates85. A flux control coefficient relates the n-
fold change in PCAD enzyme concentration to the n-fold change in flux to PCA. The high 
accumulation of PCA demonstrates that AroM  is extremely leaky and under normal condition 
in vivo the PCAD has a flux control coefficient of -1 for the chorismate pathway86. This lack of 
substrate channeling can also be ascertained from the high accumulation of PCA seen in the S. 
cerevisiae strains developed by Curran et al. However, at much higher expression of the PCAD 
in A. nidulans it was shown that there is some basal metabolic channeling through AroM to 





Thus, if there is no direct metabolic channeling though Aro1 the evolutionary advantage could 
be based on increasing the local concentration of the substrates to increase the rate of 
substrate flux through the enzymatic complex. Enzyme co-localization is observed in many plant 
systems such as dhurrin and phenylpropanoid biosynthesis80.  In prokaryotes, as previously 
mentioned, the chorismate pathway is organized as mono-functional proteins that catalyze the 
individual reactions. However, in plants and fungi that is not the case. In plants the 3-
dehydroquinase and shikimate dehydrogenase domains are organized as a single bi-functional 
protein domain fusion87. The DHQ-SDH domain of Arabidopsis thaliana has been the most 
studied and demonstrates channeling in the pathway.  
The DHQ and SDH proteins in the fusion protein are homologous to the bacterial enzymes so 
the system is highly conserved. Singh et al. crystallized the protein in the presence of shikimate, 
NADP+ and tartrate (a structural analogue of DHQ) and identified a monomeric functional state. 
The crystal structure of the protein revealed a concave architecture, which places the two 
emzyme active sites in close proximity of each other (Figure 3). This structure allows for an 
extremely processive SDH domain with a ~9-fold increase in turnover rates as compared to the 
DHQ domain or to a mono-functional SDH domain from prokaryotes. This validates the 
hypothesis of enzyme fusions promoting metabolite co-localization to increase carbon flux 
through the pathway.   
AroM from the fungi A. nidulans has also been implicated in facilitating metabolite co-
localization. Mutation studies of isolated and native 3-dehydroquinase domains demonstrate 
the that Km/Kcat ratio of the DHQase in the pentafunctional complex is 50% higher than the ratio 
in singular isolated domains88. Similarly, the catalytic effect of the isolated DHQase domain was 
160-fold lower than the wild-type pentafunctional enzyme domain in N. crassa89. Considering 
the AroM proteins from A. nidulans and N. crassa are homologs to S. cerevisiae we can safely 
conclude that there might be basal metabolite co-localization present in the chorismate 
pathway in yeast.  
The structure of Aro1 itself also shows evidence of co-functionality between the domains. The 





one containing the DHQ synthase and the 5-ESP synthase domains and the other half 
containing the shikimate kinase, DHQase and the shikimate dehydrogenase domains45 (Figure 
4). It has been shown that the different domains of the pentafunctional protein have intrinsic 
interactions with the others that affect the catalytic functionality of the domains. This is 







Figure 3. Comparison of A.thaliana DHQ-SDH protein and homologous domains of S. cerevisiae Aro1 
A) Model of the A. thaliana DHQ-SDH protein. The model was generated using the crystal structure published by 
Singh et al.
86
 The 3-dehydroquinase (DHQ) domain is on the left and the shikimate dehydrogenase (SDH) domain is 
on the right. The protein shows a concave structure that has been demonstrated to facilitate metabolic channeling 
by increasing the local concentrations of substrates.  B) Structure of S. cerevisiae Aro1 from residues 1078 - 1587. 
The model was built using the Phyre2 modeling platform and has a structural alignment at a 100% confidence with 
the A. thaliana DHQ-SDH protein. The DHQ domain is on the left and the SDH domain is on the right. The two 























protein. Multiple deletion and co-expression studies have demonstrated that the 3-ESP 
synthase domain’s catalytic functionality is directly dependent on its cis bonding to structurally 
complete DHQ synthase domain86. If the DHQ synthase domain is replaced by another folded 
Figure 4. Representation of internal structure of S. cerevisiae 
Aro1 homo-dimer. The domains are 1: DHQ synthase; 2: 5-EPS 
synthase; 3: shikimate kinase; 4: DHQase; 5: shikimate 
dehydrogenase
45
. The dimerization interface is between domains 





protein or not present in its entirety there is complete abatement of 5-ESP synthase activity. 
Similarly, the DHQase domain and the shikimate dehydrogenase domain are the dimerization 
interface for the AroM homo-dimer45. Thus, the deletion of the shikimate dehydrogenase 
domain would destabilize the dimerization of Aro1 and would have a detrimental effect on the 
functionality of the Aro1 complex as a whole and negatively affect the flux going through this 
pathway90.  
Taking all this into account we can surmise that the S. cerevisiae Aro1 protein probably does not 
have very high substrate channeling activity, although it does produce enzyme co-localization 
to increase flux though the chorismate pathway. The flux though the chorismate pathway can 
be up-regulated by removing the feedback inhibition acting on the DHAP synthase and 
separately over-expressing the AroB and AroD domains. Additionally, any major deletion in the 
Aro1 catalytic domains will change the structure of the Aro1 enzyme and negatively affect the 
flux going through it and may even ablate its activity completely.   
Therefore, to increase the accumulation of DHS for increasing the flux towards CCM 
production, four different strategies were considered (Figure 5). I hypothesized that the 
deletion of the entire Aro1 protein or modulation of the shikimate dehydrogenase active site or 
decreasing the expression level of the Aro1 protein will lead to an accumulation of DHS which 





























Figure 5. Representations of experimental plan for this study. The optimization of DHS accumulation 
in order to channel more carbon into the heterologous cis,cis-muconic acid pathway will be explored 
in four cases. The desired flow of carbon through the cell is shaded in green; the native Aro1 protein 
is shaded in red and represents the unwanted siphoning of DHS into native metabolism. Any 
modifications to Aro1 are designated in blue. 1) The chorismate pathway will be completely de-
regulated by deleting the native DAHP synthases, aro3 and aro4, and over-expressing a feedback 
inhibition resistant mutant aro4
K229L
. Additionally, the E. coli genes aroB and aroD will be expressed 
to overcome previously identified bottlenecks to DHS production. 2) aro1 will be deleted in the 
previously described strain to prevent loss of DHS to the native metabolic pathway in an attempt to 
increase CCM production. 3) The shikimate dehydrogenase domain of Aro1 will be mutated in the 
strain from Case 1 to greatly reduce conversion of DHS into shikimate. 4) Aro1 from strain one will be 
tagged with a rapid-degradation tag in order to reduce its abundance in the cell with the intention of 





1.4 Rationale and Proposed Metabolic Engineering Objectives 
 
1.4.1 Deletion of Aro1 to Increase Accumulation of 3-Dehydroshikimate  
 
Aro1 is a critical enzyme in the shikimate pathway that produces precursors for all aromatic 
amino acids and a large number or aromatic vitamins such as Vitamin B12, folate and p-
aminobenzoic acid (PABA), which are essential for growth. Removing its functionality from the 
cells metabolism has been shown to cripple the cells and to have a large negative effect on 
their growth67,91. Therefore, the growth conditions that would be feasible to grow an aro1 null 
deletion strain of S. cerevisiae will be explored using the S. cerevisiae deletion strain 
collection92. These deletion strains are based on the common laboratory strain BY4741 and are 
auxotrophic for histidine, leucine, methionine and uracil. These amino acids will be 
supplemented in the growth media to complement the auxotrophies. As the chorismate 
pathway is the precursor pathway to produce all the aromatic amino acids, ostensibly, 
supplementing the media with certain amounts of aromatic amino acids might rescue the 
growth phenotype in an aro1 null deletion. However, supplementing an industrial production 
strain with amino acids or growing the strain in rich media gets cost-prohibitive at larger scales, 
thus the resulting Δaro1 strain will also be evolutionarily adapted to minimize aromatic 
supplementation. Adaptive evolution takes advantage of selective pressure and the S. 
cerevisiae’s high DNA recombination frequency and modularity in gene expression levels to 
select for user-defined traits in the chosen organism93–95. Thus the Δaro1 strain will be grown 
with decreasing amounts of aromatic molecule supplementation in the growth media until the 
minimal amount of supplementation for viable and robust growth is determined. This method 
would be the most effective way to remove shikimate production in the cell and direct all the 








1.4.2 Mutating aro1 to Remove Shikimate Dehydrogenase Functionality to Accumulate 3-
Dehydroshikimate 
 
To avoid the drastic metabolic effect of deleting Aro1’s functionality, a more elegant solution 
would be to minimize and limit the conversion of DHS to shikimate to only what is minimally 
required for cell viability. This can be achieved by mutating the shikimate dehydrogenase active 
site in Aro1 to decrease its catalytic efficiency. The shikimate dehydrogenase domain of S. 
cerevisiae Aro1 has not been analyzed by mutation analysis. However, multiple homologs of 
prokaryotic shikimate dehydrogenases have been crystallized and their active sites determined 
96–99. The active site is divided into two domains, the NADPH binding domain and the catalytic 
domain99. There are multiple highly conserved residues throughout the protein, mostly in the 
NADPH binding module. However, there is a highly conserved lysine (K) residue in the substrate 
binding/catalytic module that has been computationally implicated in the binding of DHS98 
(Figure 6). The positively charged lysine residue at the opening of the active site is hypothesized 
to stabilize the binding of DHS to the active site. Modifying this residue into one that has a 
neutral or opposite charge would disrupt its stabilizing effect and reduce the efficiency of DHS 
binding to the active site. This lysine residue has also been targeted for mutagenesis in the A. 
thaliana bi-functional DHQ-SDH protein87. Mutating this residue to a negatively charged 
aspartic acid showed a strongly decreased shikimate dehydrogenase activity in vitro. The 
decreased binding stability of DHS to Aro1 would decrease the catalytic efficiency of the Aro1 
shikimate dehydrogenase domain, which would subsequently lead to decreased shikimate 
production and an increased accumulation of DHS in the cell.  
1.4.3 Reducing the Abundance of Aro1 to Increase 3-dehydroshikimate Accumulation 
 
Decreasing the abundance of a protein decreases the total amount of substrate converted into 
the product by the protein. The expression level of the protein and its rate of degradation 
determine its cellular abundance. The expression level of a protein is mostly determined by its 

























Figure 6. Model of the Haemophilus influenzae AroE shikimate 
dehydrogenase active site. This protein has a nearly identical 
structure to the S. cerevisiae shikimate dehydrogenase domain as it is 
highly conserved 
92
. Positive charges are colored in blue while negative 
charges are in red. The proposed 3-Dehydroshikimate (DHS) binding 
pocket is highlighted in yellow.  The positively charged lysine residue 
marked in the binding pocket stabilizes the interaction between the 
carboxylic acid group of DHS and NADPH for the reaction to occur. 
Disruption of this stabilizing function has been shown to decrease the 
interaction between the enzyme, DHS and NADPH, reducing the 





timing of the protein's expression100. Degradation of a protein can be affected by adding 
specific degradation tags on the protein, which hasten or delay the degradation process101. S. 
cerevisiae, like all other organisms has a tightly controlled cell cycle. The proteins that regulate 
entry and exit to and from each cell cycle, cyclins, must be expressed and degraded very rapidly 
to prevent overlapping cell cycles that can be deadly to the cell102. Most of the cyclins have a 
specific domain that targets the protein for degradation via the ubiquitin system103,104. Cyclins 
that mediate the G1 to S transitions in the cell have a particular degradation domain rich in 
proline, glutamine, serine and threonine (PEST domains) that specifically target the proteins for 
degradation via the constitutive ubiquitin pathway105. The PEST degradation domain from Cln2p 
has been used to tag GFP and the complete ablation of the GFP signal was observed 30 minutes 
after inoculation106. Thus, this domain will be inserted on the N' terminal of Aro1 to 
dramatically reduce its cellular abundance and subsequently increase the cellular accumulation 
of DHS.  
2. MATERIALS AND METHODS 
 
2.1 Strain and Plasmid Construction 
 
2.1.1 Construction of Plasmid Expressing Recombinant CCM Pathway 
 
All strains and plasmids used in this study are reported in Table 1. All plasmids were assembled 
using overlapping DNA parts and transformation assisted recombination in yeast102. All PCR 
amplifications of the DNA parts were done using primers listed in Table 2 and Phusion HF 
Polymerase (ThermoFisher F-530S) according to the manufacture’s recommended protocols. 
The gene encoding the Aro4K229L feedback resistant variant was amplified by PCR from a 
previously created point mutation of aro4fbr as described by Luttick et al49. The aroB and aroD 
genes were amplified from wild-type DH5 E. coli genomic DNA. The 4BD plasmid (p4BD) was 
based on the pYES high-copy plasmid system103. The 3-dehydroshikimic dehydratase, aroY from 










EV pYES2, URA3 No genes inserted 103 
4BD pYES2, URA3 tef1p–aro4
K229L
–pgiter; pgkp–aroB–adh1ter and tdh3p–





Pdc1p–aroZ–eno2ter from P. anserina; fba1p–aroY–tpiter 








–pgiter; pgkp–aroB–adh1ter and tdh3p–
aroD–adh2ter from E. coli; Pdc1p–aroZ–eno2ter from P. 
anserina; fba1p–aroY–tpiter from K. pneumoniae; pma1p–
hqd2–cycter from C. albicans 
This study 
pSH47 URA3 CRE-recombinase under Gal1 promoter 107 
Strain Genotype Plasmid Parent Strain Reference 
BY4741 MAT a; his3Δ1 leu2Δ0 met15Δ0 
ura3Δ0 
None S288C 91 
BY4741 aro1 MAT a; his3Δ1 leu2Δ0 met15Δ0 
ura3Δ0 aro1 
None BY4741 91 
13D 
Mat α; MAL2-8c; SUC2; ura3-52 









Mat α; MAL2-8c; SUC2; ura3-52; 
aro3; aro4 








Mat α; MAL2-8c; SUC2; ura3-52; 
aro3; aro4; aro1 


















K34 A1Cln2pEV aro3; aro4; ARO1-CLN2PEST EV 
K34 A1Cln2p4BD 4BD 
K34 A1Cln2p6g 6g 
 
Table 2. Primers and other guide-RNA sequences used in this study 
Primer 
Description 
Primer sequence (5’ – 3’) 
Kanamycin 
resistance cassette 


































        aroB 
FWD: ctagaaaatttattataaaaggaagagaaataattaaacaatggagaggattgtcgttactc 
REV: aaagtctattattaattggtgttgtttcagttttatgtctttacgctgattgacaatcggc 








        aroD 
FWD: ctagaaaatttattataaaaggaagagaaataattaaacaatgaaaaccgtaactgtaaaaga 
REV: aaagtctattattaattggtgttgtttcagttttatgtctttatgcctggtgtaaaatagttaatacc                   













        aroZ 
FWD: catcccatataaacatatcataaattaaattaaataaacaacatgcgactgggtgagcatatgttccg 
REV: agattattatttattaattttattatggaatcttattataaggtatcatctccatctccc 




       fba1p 
FWD: gaccacagtgatatgcatatgggagatggagatgatacctatccaactggcaccgctggc 
REV: gcgcgatggcgtcgcgcagatcctgaatcggtgcggtcattatgtattacttggttatggttatatatgac 
       aroY 
FWD: acatctaccagtcaacagccaacaattaactaattaaacaatgaccgccccaatccaagatttg 
REV: tatttttaagtagaattttgaaaatagtatttaattattattacttggcggaaccttgattcttttcc 




       pma1p 
FWD: ttgagaagatgttcttattcaaatttcaactgttatatagacaggcattgctgggatcaccc 
REV: cctaaggaggttttaacactttcagtaaaagcttgtgacattttgataattaaatctttcttatc 
       hqd2 
FWD: catcccatataaacatatcataaattaaattaaataaacaatgtcccaagccttcaccgaatctg 
REV: agattattatttattaattttattatggaatcttattatattacaacttgatttcagcatcttgtctagc 






       Vector backbone 
FWD: cctctttatattacatcaaaataagaaaataattataacacctgcattaatgaatcggccaacgcgcgggg 
REV: gcatttttattatataagttgttttattcagagtattcctgccctgtagcgccccattaagcgcgg 
       Cas9 part 
FWD: aggaatactctgaataaaacaacttatataataaaaatgcatagcttcaaaatgtttctactccttttttactc 
REV: catctgtccacttgtatgtttatgcgttttctaagaccgggcaaattaaagccttcgagcg 
























     Mutagenesis primers 
FWD: ctctggaattagacataatgcagtacatggatgaattgactgatgc 
REV: ggcgattcagaatggccaattggctttccaacaacaaacagttcc 































1,2-dioxygenase, hqd2 from C. albicans were codon-optimized and synthesized by GeneArt, 
(Life Technologies Incorporated, Burlington, ON). These genes were further sub-cloned 
individually and in combination with aro4fbr, aroB, aroD into single copy CEN/ARS based pGREG 
plasmids104 to test functionality. DNA was transformed into S. cerevisiae CEN.PK 13D105 strains 
using the lithium acetate heat shock method as described by Gietz et al106.  
2.1.2 Yeast Genes Deletion 
 
Aro4 and aro3 were deleted in complementary mat-a and mat-α strains using homologous 
recombination and selection on 200µg/ml of G418 and hygromycin, respectively as previously 
described107. Isolated colonies under antibiotic selection were picked and the presence of the 
deletion was confirmed by PCR on extracted genomic DNA. The cognate mat-a and mat-α 
strains were then plated on the same YPD plate and left to mate overnight at 30˚C. The mated 
cells were streaked to isolate single colonies and diploid cells were identified based on size and 
shape using a light microscope. These diploid cells were streaked on pre-sporulation media 
(Bacto-Yeast Extract 8 g/L, Bacto-Peptone 3 g/L, Dextrose 100 g/L, Agar 20 g/L) followed by 
sporulation media (Potassium Acetate 10 g/L, Bacto-Yeast Extract 1 g/L, Dextrose 500 mg/L, 
Agar 20 g/L) for 4 days each in order to recover haploid cells108. These cells were confirmed to 
be haploids by their size and shape under the light microscope and by performing a mating test 
with known haploid strains. The confirmed haploids cells were selected on YPD plates 
containing both G418 and hygromycin to select for both aro3 and aro4 deletions. Isolated 
colonies under antibiotic selection were selected and the presence of both the deletions was 
confirmed by PCR on extracted genomic DNA. The double deletion strain was cured of the loxP-
flanked antibiotic selection cassettes using a Cre recombinase and replica plating was used to 
identify colonies with no antibiotic resistance. The cured double deletion strain S. cerevisiae 
CEN.PK 13D ura3 aro4 aro3 was named K34. Strain K34 was used as a base strain to create all 
other strains used in this study. The aro1 deletion was made and selected for using the same 
LoxP-flanked G418-selection based homologous recombination cassette. The resulting strain, S. 
cerevisiae CEN.PK 13D ura3 aro4 aro3 aro1, was verified using PCR on extracted genomic DNA 





2.1.3 Modification of Chromosomally Encoded Aro1  
 
The Aro1K1372E point mutant was created in a two-step process (Figure 7). The shikimate 
dehydrogenase domain active site of the aro1 coding region was amplified by PCR and inserted 
into a pYES vector using the Gibson assembly method109. Site-directed mutagenesis (SDM) of 
the selected active site region was performed using a QuickChange protocol (ThermoFisher) 
and the primers listed in Table 2. The resulting plasmid containing the modified active site was 
transformed into E. coli and subsequently sequenced to confirm the location of the point 
mutation. To facilitate a scar-less insertion of the modified active site back into the native aro1 
coding region, two rounds of CRISPR-based recombination110 were used. Firstly, a 20-bp non-
native stretch of DNA (stuffer region) was inserted into the target region of aro1 of strain K34 
(see Table 2 for gRNA and stuffer sequence used). The point mutant version of the active site 
DNA fragment previously created by SDM was then amplified by PCR and used as a donor in a 
second round of CRISPR, targeting the non-native stuffer region as the cleavage site. The 
chromosomally-encoded modified shikimate dehydrogenase domain was amplified by PCR 
from several clones and sequenced to confirm the presence of the mutation. This resulted in a 
scar-less insertion of a mutation of aro1 in a K34 based strain. This strain, S. cerevisiae CEN.PK 
13D ura3 aro4 aro3 aro1K1370E, was named K34M. 
The Cln2 tag was inserted at the 3’ end of aro1 to act as a rapid degradation tag101. The piece of 
DNA to be inserted into the chromosome was created in three parts. The PEST domain from 
cln2 was amplified with 50 bp homology to the 3’ end of aro1 on either side of the domain. 
Additionally, two 500 bp regions from the 3’ of aro1 were amplified to overlap the 50bp of aro1 
homology on the PEST domain. (See Table 2 for primers used) DNA soeing (splicing by overlap 
extension) using PCR amplification was subsequently used to combine the three pieces of DNA 
to create one piece of DNA containing the cln2 PEST domain flanked by 500 bp of homology to 
the 3’ end of aro1 on either side. This piece of DNA was then used as a donor in a CRISPR-
assisted insertion targeting the 3’region of aro1. Several isolated colonies were picked and 
correct insertion of the Cln2 tag was confirmed by PCR amplification of the genomic region 










The resulting strain, S. cerevisiae CEN.PK 13D ura3 aro4 aro3 aro1-cln2PEST was named K34A1Cln2. 
 
2.2 Strain Growth and Fermentation Conditions 
 
All reagents were purchased from Sigma Aldrich Canada unless specifically mentioned. YPD 
medium (broth or 1% (w/v) agar plates) was used for antibiotic selection. Growth for testing of 
the strains for metabolite production was done in 25-ml shake flasks with YNB + 0.25 X Dropout 
medium + 2% (w/v) glucose + 35 mg/L tryptophan. All strains were inoculated into testing 
media from stationary phase overnight cultures at a 5% (v/v) inoculum. Testing of the viable 
growth conditions of the aro1 deletion K341 strain was performed in 25 ml of YNB + 2% glucose 
+ 1X vitamin mix (biotin 2 µg/L, calcium pantothenate 400 µg/L, folic acid 2 µg/L, inositol 2 
mg/L, nicotinic acid 400 µg/L, p-aminobenzoic acid 200 µg/L, pyridoxine HCl 400 µg/L, riboflavin 
200 µg/L and thiamine HCL 400 µg/L) and varying concentrations of dropout media; 3X, 2X, 1X, 
0.5X, 0.25X and no dropout media. All O.D. readings were performed using a Cary 50 (Agilent 
Technologies Mississauga, ON) at 600nm.  
Two-step fermentation with different growth media at each step was performed similar to the 
methodology described by Horwitz et al90. Strain K341 p6g (Table 1) was inoculated from a 
stationary phase culture into 25 ml of YPD broth in 250 ml erlenmeyer flasks and incubated at 
30˚C and 250 RPM for 48 hours.  The cells were pelleted at 4000 X g for 5 minutes and washed 
twice in 10 ml of deionized water. The cells were subsequently added to 25 ml of YNB + 4% 
glucose and incubated at 30˚C and 250 RPM for a further 72 hours. O.D. 600 readings and 
samples were taken at regular intervals to quantify metabolite accumulation.  
Anaerobic cultures were first grown under aerobic conditions for 36 hours at 30˚C. At 36 hours, 
1 ml of 25 mg/ml glucose was added to the cultures and the headspace was replaced with 
nitrogen gas. These cultures were subsequently sealed with Parafilm and aluminum foil, capped 
tightly and incubated at 30˚C and 250 RPM for 48 hours. The caps and the seal were then 
removed and the strains were allowed to ferment aerobically for 36 more hours. O.D. readings 





2.3 Metabolite Identification and Analysis 
 
All metabolite were measured from the culture supernatants. For preparation of samples to be 
analyzed, 300 µL of cell culture was collected and 250 µL of the supernatant was retained after 
centrifugation at 13000 X g for 5 minutes. The supernatants were subsequently filtered using 
nitrocellulose syringe filters (Cole-Parmer, RK-02915-53) to remove cell mass and debris. 
Twenty µL of supernatant was injected per analysis. The metabolites were identified using HPLC 
equipped with a UV/Vis detector (Thermo Surveyor) and a Waters 3100 refractive index 
detector. A Bio-Rad ion exchange column Aminex HPX-87H was used with 10 mM sulphuric acid 
as an isocratic mobile phase with a flow rate of 0.6 mL/min. Shikimate, DHS, pyruvate, acetate, 
protocatechuic acid, catechol and CCM were analyzed using a UV/Vis detector at standard 
wavelengths of 210 and 280 nm. Glucose and ethanol were measured using their refractive 
index. All measurements were compared to linear standard curves of reference standards. 
3. RESULTS  
 
3.1 Removing Feed-back Inhibition in the Chorismate Pathway 
 
The first step in the over-accumulation of DHS was to maximize the carbon flux entering the 
chorismate pathway. The pathway is feedback-inhibited by its downstream products, tyrosine 
and phenylalanine. At cellular concentrations above basal metabolic levels tyrosine and 
phenylalanine inhibit the activity of Aro3 and Aro4, limiting the amount of carbon entering the 
chorismate pathway41. This was overcome by the deletion of the native feedback-inhibited 
DAHP synthases, aro3 and aro4, as previously described by Luttick et al.49 and overexpression 
of the feedback-resistant Aro4K229L mutant. The accumulation of DHQ has also been previously 
identified as the second bottleneck in the early chorismate pathway52. To this effect, a plasmid, 
p4BD, expressing a feedback resistant Aro4 (Aro4fbr), AroB and AroD was transformed into the 
wild-type and feed-back resistant strains. Upon growth on minimal media, the feedback-





22mg/L of shikimic acid (Figure 8D) as compared to the wild-type strain (Strain 13D pEV), which 
only accumulated 13.1 ± 1 mg/L of shikimic acid demonstrating the effectiveness of the 
engineered pathway. Strain K34 p4BD also accumulated 28.3 ± 1.9 mg/L of DHS representing a 
2-fold improvement over the wild-type strain over-expressing p4BD (13D p4BD, Table 1) (Figure 
8C). Strain 13D pEV shows much slower growth rate and glucose consumption rate as 
compared to the other strains; this is an artifact caused by a smaller starting concentration of 
cells (Figure 8A & 8B). The large accumulation of shikimic acid suggests that Aro1 was 
converting the accumulated DHS into downstream precursors of the chorismate pathway.  
Thus, the Aro1 node needs to be modulated to prevent accumulation of shikimic acid. This can 
be done in three ways; the entire aro1 gene could be deleted from the strain ablating the 
encoded functionality completely; the shikimate dehydrogenase domain of Aro1 can be 
targeted for mutagenesis to effectively and precisely knock out its functionality; and the 
abundance of the entire Aro1 protein in the cell can be diminished to reduce its effectiveness at 
converting DHS to shikimic acid.   
3.2 Deletion of Aro1 and its Effect on DHS Accumulation  
 
The deletion of Aro1 functionality from the cell should remove DHS utilization for cellular 
metabolism and lead to its accumulation as shown by Horwitz et al.91. As Aro1 is essential in the 
chorismate pathway and produces precursors that lead to all aromatic molecule production in 
the cell, its deletion could have adverse effects on the growth of the cell. The Yeast Deletion 
Library92 was used to test the feasibility of creating a strain with no Aro1 functionality. The 
BY4741 Δaro1 strain was grown in synthetic complete (SC) media with the different aromatic 
amino acids as sole aromatic molecule sources (Table 3). The amino acid supplement contained 
76 mg/L of tyrosine and phenylalanine and was used as a baseline to screen the aromatic 
molecule supplements. The growth phenotype of the Δaro1 strain was not rescued by the 







Table 3. Investigation of growth conditions of Δaro1 S. cerevisiae strains. # represents the 
number of colonies observed on the plate. 
CONDITIONS STRAIN Y/N (#) 
YPD BY 4741 ΔAro1 Y 
YNB Δa.a DO (Synthetic complete Drop-out) +2% 
Glucose 
BY 4741 N 
YNB Δa.a DO +2% Glucose BY 4741 ΔAro1 N 
YNB + a.a DO +2% Glucose BY 4741 Y 














 + a.a DO + 2% Glucose BY 4741 ΔAro1 N 







 + a.a DO + 2% Glucose + 25 mg/L 
Chorismate 
BY 4741 ΔAro1 N 
YNB + a.a DO + 2% 
Glucose (BY 4741 ΔAro1) 
Y/N (#) YNB Δ(NH4)2SO4 + a.a DO + 
2% Glucose (BY 4741 ΔAro1) 
Y/N (#) 
30 mg/L Tyrosine + 40 
mg/L Tryptophan + 50 
mg/L Phenylalanine 
Y 
30 mg/L Tyrosine + 40 
mg/L Tryptophan + 50 
mg/L Phenylalanine 
Y 
60 mg/L Tyrosine Y 
60 mg/L Tyrosine Y (267) 
180 mg/L Tyrosine Y (102) 
40 mg/L Tryptophan Y 
40 mg/L Tryptophan Y (181) 


















40 mg/L Tryptophan + 
60 mg/L Tyrosine 
Y (184) 
40 mg/L Tryptophan + 
60 mg/L Tyrosine 
Y (313) 
























Figure 8. Comparison of growth and metabolite accumulation by strains K34pEV, 
K34p4BD, 13DpEV and 13Dp4BD. They are represented by (   ), (    ), (   ) and ( x ) 
respectively. A) Growth profiles of the 4 strains as grown in 50 ml YNB+2%glucose+0.1X 
dropout+35mg/L tryptophan. B) Glucose consumption by the four strains. 13DEV 
consumes glucose slower than the other strains. C) 3-Dehydroshikimate (DHS) 
accumulation by the strains. D) Shikimate accumulation of the 4 strains. K34p4BD 
accumulates 369.9 ± 29.2 mg/L of shikimate as compared to 13.1 ± 1.6 by 13DpEV.  All 
errors represent standard deviation of biological triplicates.  





Chorismate was not able to rescue growth phenotype in the presence or absence of ammonium 
sulphate as a nitrogen source either116. Additional amounts of phenylalanine inhibited growth 
even in the presence of tyrosine. However, the growth phenotype was rescued by tryptophan, 
even in the presence of phenylalanine. Tryptophan and tyrosine both rescued the growth 
phenotype of the Δaro1 strain, however, tryptophan was chosen as the aromatic molecule 
substitute as a lesser amount of it was necessary to restore growth.  
The aro1 gene locus was completely deleted from the K34 strain using homologous 
recombination with LoxP-flanked antibiotic cassettes112. The resulting CEN.PK aro3 aro4 aro1 
ura3 strain was named K341 (Table 1). As expected, it had a poor growth phenotype on minimal 
or synthetic complete media. The optimum growth conditions for K341 were determined by 
growing it in different concentrations of amino acid and vitamin supplementation (Figure 9A). 
Three times the manufacturer’s recommended amount of supplementation was required to 
achieve K34 levels of growth. Supplementing the growth media with large amounts of aromatic 
molecules is not economically feasible, thus K341 was evolutionarily adapted to grow on 
increasingly lower amount of vitamins and amino acid supplements by growing it repeatedly 
and for extended periods of time in minimal media with 0.5X amino-acid dropout supplement, 
35 mg/L of tryptophan but no vitamins. After multiple rounds of passage, wild-type growth 
phenotype was observed while growing K341 (Figure 9B). This strain was used in all further 
experiments.  
Strain K341 pEV accumulated 14.1 ± 1 mg/L of DHS without overexpressing p4BD as compared 
to 9.3 ± 1.2 mg/L DHS accumulated by K34 pEV (Figure 10C). It was also observed, as expected, 
that there was no presence of shikimate in the cell culture (Figure 10C). However, upon 
overexpression of Aro4fbr,AroB and AroD (p4BD) in strain K341, there was about 26.6 ± 1.6 mg/L 
of DHS accumulated in the cell culture, comparable to its accumulation in strain K34 p4BD (no 
aro1 deletion). The deletion of aro1 led to complete abatement of shikimate production and a 
2-fold increase in DHS production as compared to the wild-type 13D strain over-expressing 
Aro4fbr,AroB and AroD (p4BD). However, the deletion also caused the strain to be non-viable on 














Figure 9. Effects of varying concentrations of dropout media supplementation and 
evolutionary adaptation on growth profiles of K341. A) Effects of varying 
concentrations of droput (DO) media supplementation on growth profiles of non-
viable K341pEV strains. The highest concentration of DO supplementation, 3x is 
represented by (  ); 2x DO supplementation is represented by (x); 1x DO is 
represented by (  ); 0.5x DO is  represented by (  ) and 0.25x DO is represented by (  ). 
B) The effect of multiple rounds of evolutionary adaptation on the growth profile of 
K341pEV. 13DpEV (wild-type) is represented by (  ); K341pEV before adaptation is 




















Figure 10. Comparison of growth and metabolite accumulation by strains K341pEV, 
K341p4BD, 13DpEV and 13Dp4BD. They are represented by (   ), (    ),  (   ) and ( x ) 
respectively. A) Growth profiles of the 4 strains as grown in 50 ml YNB+2%Glucose+0.1X 
Drop-Out+35mg/L tryptophan. B) Glucose consumption by the four strains. 13DpEV 
consumes glucose slower than the other strains. C) 3-Dehydroshikimate (DHS) 
accumulation by the strains. 13Dp4BD and K341p4BD accumulate more DHS than their 
cognate strains not expressing the p4BD plasmid. K341p4BD has a maximum 
accumulation of 27.1 ± 1.6 mg/L of DHS D) Shikimate accumulation of the 4 strains. All 
errors represent standard deviation of biological triplicates.  





Thus, in order to have the minimal possible modification to cellular metabolism, a mutation 
that would minimize the conversion of DHS to shikimate by altering the active site of Aro1 was 
also pursued. 
3.3 Effect of Mutations in Aro1 on Cellular DHS Accumulation 
 
As deletion of aro1 results in a large negative effect on cellular metabolism, its functionality 
must be diminished another way. Precise removal of the shikimate dehydrogenase domain of 
Aro1 would be preferable to the complete deletion of the protein. Weber et al.67 attempted 
this by deleting the entire shikimate dehydrogenase domain. However, this strain was also 
auxotrophic for aromatic molecules and had to be rescued by overexpression of E. coli homolog 
AroE. As has been shown before, Aro1 does not have distinct metabolic channeling functions85 
and merely deleting the domain from the pentafunctional enzyme and replacing it with the 
cognate E. coli functional enzyme, AroE, would not have much of an effect in dampening the 
conversion of DHS to shikimic acid. Additionally, it has also been shown that any disruption in 
the tertiary and quaternary structure of Aro1 has negative effects on its function90. Aro1 
functions as a homo-dimer with the shikimate dehydrogenase domain as one of the 
dimerization interfaces. Thus, deletion of the shikimate dehydrogenase domain would have 
some adverse effects on Aro1’s functionality. On the other hand, mutation of the active site of 
the shikimate dehydrogenase domain to decrease its catalytic activity would have the desired 
effect of disrupting the conversion of DHS to shikimic acid.  
There are multiple highly conserved amino acid residues in the shikimate dehydrogenase active 
site that convert DHS to shikimate using NADPH as a cofactor. Most of these residues are in the 
NADPH binding domain; however there is a conserved lysine (K) residue in the DHS binding 
pocket that has been implicated in DHS binding stabilization. This residue was targeted and a 
single point mutation was made using CRISPR mediated recombination changing the positively 
charged lysine residue into a negatively charged glutamic acid residue with the intention of 
disrupting the stabilizing effect. This strain, S. cerevisiae CEN.PK 13D aro3 aro4 ura3 aro1K1370E 





K34M showed wild-type growth and glucose consumption phenotypes in minimal media in the 
presence or absence of Aro4fbr,AroB and AroD (p4BD) over-expression without any need for 
evolutionary adaptation (Figure 11A& 11B). Without the over-expression of proteins encoded 
by p4BD K34M pEV accumulated 8.5 ± 0.2 mg/L of DHS, comparable to DHS accumulation in 
strain K34 pEV and double the DHS accumulation in wild-type strain 13D pEV (Figure 11C). 
Over-expression of Aro4fbr,AroB and AroD (p4BD) in K34M results in an accumulation of 43 ± 1.9 
mg/L of DHS. This is 1.5-fold increase in the DHS accumulated by the strains K34 p4BD and K341 
p4BD. Strain K34M p4BD also had a drastically reduced accumulation (≈20-fold less) of 
shikimate, 4.8 ± 0.1 mg/L, as compared to strain 13D p4BD, 80.5 ± 1.8 mg/L (Figure 11D). K34M 
p4BD also had a 79-fold decrease in shikimate accumulation as compared to K34 p4BD. Thus, 
modulating the catalytic activity of Aro1 resulted in an increased accumulation of DHS and a 
decrease in shikimate production. Along with the catalytic functionality of Aro1, the abundance 
of Aro1 and its effect on DHS accumulation was also investigated.  
3.4 Effect of Decreasing the Abundance of Aro1 on DHS Accumulation 
 
The mutation of the shikimate dehydrogenase domain in Aro1 dramatically reduces the 
conversion of DHS to shikimate, increasing the intracellular pool of DHS.  This resulted in more 
carbon being diverted from native metabolism into the heterologous pathway.  
A similar effect can also be achieved by decreasing the abundance of the entire Aro1 as a 
whole. Decreasing Aro1’s abundance will decrease the number of enzymatic domains in the cell 
that can convert DHS to shikimate causing a greater accumulation of DHS. This was achieved by 
tagging the Aro1 protein with a constitutive degradation tag that rapidly degrades the protein. 
Most of these tags originate from cyclin proteins that control cell cycle, hence their expression 
and degradation is tightly controlled to prevent cell-cycle de-regulation. Cln2 is a S. cerevisiae 
G1-cyclin that is involved in the G1 to S phase transition and is subsequently rapidly degraded. 



















Figure 11. Comparison of growth and metabolite accumulation by strains K34MpEV, 
K34Mp4BD, 13DpEV and 13Dp4BD. They are represented by (   ), (    ),  (   ) and ( x ) 
respectively. A) Growth profiles of the 4 strains as grown in 50 ml YNB+2%Glucose+0.1X 
Dropout+35mg/L tryptophan. B) Glucose consumption by the four strains. 13DpEV 
consumes glucose slower than the other strains. C) 3-Dehydroshikimate (DHS) 
accumulation by the strains. K34Mp4BD has a maximum accumulation of 43.1 ± 1.9 mg/L of 
DHS. D) Shikimate accumulation of the 4 strains. 4.7 ± 0.1 mg/L is the maximum shikimate 
accumulated by K34Mp4BD. All errors represent standard deviation of biological triplicates.  





sequence (PEST tag) that targets the protein for degradation by the constitutive ubiquitin 
pathway. 
The PEST tag from Cln2 was inserted in the 3’ end of Aro1 using CRISPR mediated 
recombination. This strain, S. cerevisiae CEN.PK 13D aro3 aro4 ura3 aro1-Cln2PEST, was named 
K34A1Cln2 (Table 1).  
Strains K34A1Cln2 pEV and K34A1Cln2 p4BD showed wild-type growth profiles in minimal 
media demonstrating that there was no detrimental effect on cell viability (Figure 12A& 12B). 
K34A1Cln2 pEV accumulated only 0.8 ± 0.1 mg/L of DHS which is 4-fold less than the amount of 
DHS accumulated by 13D pEV (Figure 12C). Strain K34A1Cln2 p4BD accumulated 32.3 ± 3.3 
mg/L of DHS, which is greater than the amount of DHS accumulated by strains K34 p4BD and 
K341 p4BD and double the amount of DHS accumulated by strain13D p4BD. Strain K34A1Cln2 
pEV also accumulated 11.1 ± 0.2 mg/L of shikimate which is less than the amount of shikimate 
accumulated by strain 13D pEV (13.1 ± 1 mg/L), but greater than the amount accumulated by 
strain K34M pEV, 2.1 ± 0.1 gm/L (Figure 12D). Expression of Aro4fbr,AroB and AroD (p4BD) in 
K34A1Cln2 increased shikimate accumulation to 94.8 ± 3.5 mg/L, which is 20-fold higher than 
the shikimate accumulation in strain K34M p4BD and comparable to the shikimate 
accumulation in 13D p4BD. However, the shikimate accumulation in strain K34A1Cln2 p4BD is 
4-fold smaller than the accumulation in strain K34 p4BD demonstrating the effectiveness of 
degrading Aro1 in the effort to increase the accumulation of DHS by decreasing the conversion 
of DHS to shikimate. De-regulation of the feedback inhibition in the aromatic pathway and 
over-expression of the AroB and AroD enzymes coupled with the decrease in the shikimate 
dehydrogenase activity in Aro1 has resulted in strains that accumulate a greater amount of DHS 
and smaller amounts of shikimate as compared to wild-type strains without any discernable 
decrease in growth fitness (Figure 13). These strains would be more efficient at diverting carbon 



























Figure 12. Comparison of growth and metabolite accumulation by strains 
K34Cln2MpEV, K34Cln2p4BD, 13DpEV and 13Dp4BD. They are represented by (   ),(    ),  
(   ) and ( x ) respectively. A) Growth profiles of the 4 strains as grown in 50 ml 
YNB+2%Glucose+0.1X Dropout+35mg/L tryptophan. B) Glucose consumption by the 
four strains. 13DEV consumes glucose slower than the other strains. C) 3-
Dehydroshikimate (DHS) accumulation by the strains. K34Cln2p4BD has a maximum 
accumulation of 32.3 ± 3.9 mg/L of DHS D) Shikimate accumulation of the 4 strains. 
K34Cln2p4BD has a markedly decreased accumulation of shikimate as compared to 









Figure 13. Comparison of the maximum accumulation of shikimate and 3-
dehydroshikimate (DHS) in 13Dp4BD, K34p4BD, K341p4BD, K34Mp4BD and 
K34Cln2p4BD. K34p4BD has the maximum accumulation of shikimate at 369.9 ± 22.2 
mg/L and K34Mp4BD has the lowest at 4.8 ± 0.1 mg/L. K34Mp4BD also accumulated 
the largest amount of DHS in the compared strains at 43.1 ± 1.9 mg/L. All standard 





3.5 Effect of Optimizing DHS Accumulation on Carbon Flux into Heterologous CCM 
Pathway 
 
Cis, cis-Muconic acid (CCM) is a heterologous compound that is produced from native aromatic 
molecule precursors via a heterologous enzyme pathway. 3-Dehydroshikimate (DHS) is 
converted into protocatechuic acid (PCA) via a DHS dehydratase, AroY, from P. anserina. PCA is 
decarboxylated to catechol by a protocatechuic acid decarboxylase (PCAD), AroZ from K. 
pneumoniae. Catechol is finally converted to CCM via an oxygen-dependent ring opening step 
catalyzed by a catechol-di-oxygenase (CDO), Hqd2, from C. albicans. The production of CCM 
depends on the amount of carbon diverted into the pathway from native aromatic molecule 
biosynthesis and the catalytic efficiency of the heterologous enzymes.  
In the previous section the accumulation of DHS as a precursor was optimized by removing the 
native feedback inhibition on the aromatic pathway and minimizing the conversion of DHS into 
shikimate. In order to increase DHS accumulation, by minimizing its conversion to shikimate, 
the native Aro1 was deleted or modified to reduce its functionality. In this section the effects of 
these modifications on the production of CCM and its precursors will be explored.  
Addition of the 6 gene plasmid to the wild-type 13D strain (Strain 13D p6g, Table 1) resulted in 
the production of PCA, catechol and CCM. After 120 hours of shake flask cultivation in minimal 
media with supplementation there was an accumulation of 157.5 ± 3.2mg/L of PCA 
demonstrating that carbon was being channeled from native metabolism into the heterologous 
CCM pathway (Figure 14D). There was also 23.7 ± 0.2 mg/L of shikimate being accumulated 
(Figure 14C). This implies that there was still a large amount of shikimate being produced by the 
cells. Further down the heterologous pathway, 0.53 ± 0.05 mg/L of catechol and 1.59 ± 0.08 
mg/L of CCM were accumulated, validating the functionality of the heterologous pathway 
(Figure 14 E& 14F). This strain also accumulated 2.66 ± 0.15 mg/L of DHS, which is considerably 
less than the DHS accumulated by strain 13D p4BD, which is not expressing the CCM producing 
pathway (Figure 14B). So, this demonstrates the functionality of the CCM pathway in 
















Figure 14. Comparison of growth and metabolite accumulation by strains 13Dp6g, 
K34p6g, K341p6g, K34Mp6g and K34A1Cln2p6g. They are represented by (   ),(    ),  (   ), 
( x ) and (   ) respectively. A) Growth profiles of the 5 strains as grown in 50 ml 
YNB+2%Glucose+0.1X Dropout+35mg/L tryptophan. B) 3-dehydroshikimate (DHS) 
accumulation by the strains. K341p6g and K34p6g, at 16.8 ± 0.4 mg/L and 14.5 ± 0.2 
mg/L, accumulate more DHS than the other measured strains. C) Shikimate 
accumulation of the 5 strains. D) Accumulation of protocatechuic acid (PCA) in the 
strains. K34Mp6g accumulates the greatest amount of PCA at 413.2 ± 8.4 mg/L. E) 
Catechol accumulation of the 5 strains. K34Mp6g accumulated the greatest amount of 
catechol and 13Dp6g accumulated the least. F) Accumulation of cis,cis-muconic acid 
(CCM) in the strains. K34Mp6g accumulates the greatest amount of CCM and 13Dp6g 
accumulated the least. Errors bars represent standard deviation of biological triplicates.  





As the functionality of the heterologous pathway was validated, it was introduced in the strains 
that were optimized for DHS accumulation.  
 
3.5.1 Effect of Complete De-Regulation of the Chorismate Pathway on CCM Production 
 
Strain K34 expressing Aro4fbr, AroB, AroD, AroZ, AroY and Hqd2 (p6g) (Strain K34p6g, Table 1) 
displays a diminished growth profile as compared to K34 pEV and K34 p4BD (Figure 14A). This 
strain accumulated 260.2 ± 9.2 mg/L of PCA after a 120-hr fermentation (Figure 14D). As 
expected, this was a greater accumulation of PCA as compared to 13D p6g. Strain K34 p6g also 
accumulated 72.7 ± 4.7 mg/L of shikimate which is a 3-fold increase as compared to 13d p6g 
(Figure 14C). However, K34 p4BD accumulated 369.9 ± 22 mg/L of shikimate, so a significant 
amount of carbon is being channeled into the heterologous pathway in K34 p6g. Strain K34 p6g 
also accumulates 0.58 ± 0.04 mg/L of catechol and 2.43 ± 0.15 mg/L of CCM, a slight increase 
compared to the accumulation in 13D p6g (Figure 14 E& 14F). Strain K34 p6g also had a 
maximum DHS accumulation of 14.5 ± 0.2 mg/L which then was consumed by the cells to 
achieve a final accumulation of 10 ± 1 mg/L (Figure 14B). This represents more than a 50% 
decrease from the DHS accumulation in strain K34 p4BD demonstrating that carbon was being 
efficiently into the heterologous pathway but there is still room for improvement. As there is 
still 72.7 ± 5 mg/L of shikimate being accumulated by the over-expression of chorismate 
pathway and heterologous genes, the production of CCM was investigated in strains with 
modified Aro1 functionality. 
3.5.2 Effect of Ablation of Aro1 Functionality on Carbon Flux Towards CCM Production 
 
Similar to K34 p6g, strain K341 p6g (Table 1) also had a diminished growth profile as compared 
to K341 p4BD (Figure 14A). This might be due to the metabolic burden associated with the 
over-expression of three more enzymes for the heterologous pathway. K341 has a complete 
ablation of all Aro1 activity and has demonstrated a complete lack of shikimate production 





heterologous CCM pathway was expressed in this strain (K341 p6g) it accumulated 214.1 ± 
2mg/L of PCA with no quantifiable shikimate production (Figure 14D). This is a slightly smaller 
accumulation of PCA as compared to strain K34 p6g. K341 p6g also accumulated more catechol 
and CCM, 0.78 ± 0.16 mg/L and 2.52 ± 0.22 mg/L respectively, as compared to K34 p6g (Figure 
14 E&F). Surprisingly, strain K341 p6g had a significantly higher final accumulation of DHS, 16.8 
± 0.4 mg/L, as compared to strain K34 p6g (Figure 14B). This is still a major decrease from the 
amount of DHS accumulated by strain K341 p4BD; however, it highlights some carbon 
channeling problems into the CCM pathway. 
3.5.3 Effect of Aro1K1370L Mutation on Carbon Flux Towards CCM Production 
 
The K34M strain incorporated a mutation in Aro1’s shikimate dehydrogenase domain that 
disrupts DHS binding to the active site, effectively increasing the accumulation of DHS by 
preventing its conversion to shikimate. K34M p4BD accumulated large amounts of DHS and 
minimal amounts of shikimate. So it should be capable of channeling large amounts of DHS into 
the CCM pathway. Strain K34M p6g (Table 1) shows a decrease in its final biomass 
accumulation as compared to K34M p4BD (Figure 14A). This is consistent with the observations 
on strains K34 p6g and K341 p6g. Strain K34M p6g accumulated the largest amount of PCA 
measured in this study at 419.2 ± 8.3 mg/L (Figure 14D). This is a 2.7-fold greater accumulation 
of PCA as compared to strain 13D p6g, and is 1.6- and 1.9-fold greater than the amount of PCA 
accumulated by K34 p6g and K341 p6g respectively. Strain K34M p6g also accumulated 9.3 ± 
2.3 mg/L of shikimate (Figure 14C). This is 1.4-fold less than the basal amount of shikimate 
accumulated by the wild-type strain not over-expressing any of the chorismate pathway 
enzymes (strain 13D pEV). Strain K34M p6g also accumulated small amounts of DHS at 7.3 ± 0.7 
mg/L (Figure 14B). This is comparable to the basal amount of DHS accumulated by strain 13D 
pEV. So, most of the carbon going into the chorismate pathway was successfully diverted into 
the CCM pathway. Using all this carbon, strain K34M p6g accumulated 1.02 ± 0.19 mg/L of 
catechol and 2.91 ± 0.24 mg/L of CCM (Figure 14E & 14F). This accumulation would point to 
significant carbon flux problems downstream of PCA production in the CCM pathway, as 





DHS into shikimate and further native aromatic molecules and channels more carbon towards 
CCM production.  
3.5.4 Effect of Decreasing Aro1 Abundance on Carbon Flux Towards CCM Production 
 
As seen earlier (Figure 12), decreasing the abundance of Aro1 had considerable effects on DHS 
accumulation. Strain K34A1Cln2 p4BD accumulated 32.3 ± 3.3 mg/L of DHS (double the 
accumulation in strain 13D p4BD) and only 11.1 ± 0.2 mg/L of shikimate (comparable to strain 
13D pEV). Expression of the CCM pathway in this strain should divert most of the carbon away 
from the native chorismate pathway. 
Expression of the CCM pathway in strain K34A1Cln2 (K34A1Cln2 p6g, Table 1) resulted in a 
diminished growth profile as observed before with all the CCM producing strains (Figure 14A). 
K34A1Cln2 p6g accumulated 249.5 ± 7.6 mg/L of PCA, which is comparable to the PCA 
accumulation in strain K34 p6g and 1.2- and 1.6-fold higher than the PCA accumulation in 
strains K341 p6g and 13D p6g, respectively (Figure 14D). Thus, even with the partial loss of the 
native AroB and AroD functionality, which is present in strain K34 p6g, it was able to divert 
similar amounts of carbon into the CCM pathway. Strain K34A1Cln2 p6g also accumulated only 
11.6 ± 1.4 mg/L of shikimate in the culture (Figure 14C). This is comparable to the shikimate 
accumulation in strains K34M p6g and 13D pEV and 8-fold smaller than the shikimate 
accumulation observed in strain K34 p6g, which points to the success of the DHS accumulation 
optimization strategy. After 120 hours of fermentation, strain K34A1Cln2 p6g accumulated 0.56 
± 0.09 mg/ of catechol and 2.25 ± 0.27 mg/L of CCM (Figure 14E& 14F). This is comparable to 
the catechol and CCM accumulation in all the other strains further giving strength to the 
argument that there are severe carbon flux problems further down the CCM pathway.  
Comparing the PCA and shikimate accumulation in the strains expressing the CCM pathway will 
identify the strain that was most efficient in diverting carbon from the native aromatic pathway 
into the heterologous CCM pathway (Figure 15). Strain K341 p6g accumulated no shikimate as 
expected, however as the strain cannot be grown without supplementation it has a major 















Figure 15. Comparison of the maximum accumulation of shikimate and 
protocatechuic acid (PCA) in CCM producing strains. K34Mp6g has the maximum 
accumulation of PCA at 413.2 ± 8.4 mg/L and 13Dp6g has the lowest at 157.5 ± 3.2 
mg/L. K34Mp6g also accumulated the smallest amount of shikimate in the compared 






as compared to all the other strains and have non-affected growth profiles. Out of these strains, 
K34M p6g accumulated the greatest amount of PCA at 413.2 ± 8.4 mg/L. Thus, strain K34M is 
the best choice for a CCM producing host strain as it converted the most amount of carbon 
going into the chorismate pathway to PCA with the smallest accumulation of shikimate and 
downstream native aromatic molecules. Optimizing DHS accumulation and channeling it into 
the CCM pathway has resulted in large increases in the amount of PCA produced by the strains. 
However, not all the carbon in the form of glucose is converted to PCA. There are still large 
carbon sinks present in the cell. 
3.6 Accumulation of Fermentation By-Products as Unwanted Carbon Sinks  
 
As S. cerevisiae consumes carbon, in the form of glucose, aerobically or anaerobically it 
produces ethanol and acetate as by-products of fermentation, usually, to balance important 
redox cofactors in the cell (Figure 2). Thus, a significant portion of the carbon consumed by the 
cell gets converted to ethanol and acetate.  As the conversion of DHS to shikimate is NADPH 
dependent, removing the shikimate dehydrogenase functionality and increasing the carbon flux 
into the chorismate pathway will likely have an effect on ethanol and acetate accumulation in 
the cell. Moreover, as the complete chorismate pathway consumes additional glycolytic 
precursors apart from the first condensation step between E4P and PEP, changing the flux 
through this pathway might create metabolic bottlenecks that could result in changes to 
ethanol and acetate production. To this effect, the ethanol and acetate accumulations in each 
of the strains were measured.  
Without any over-expression of the chorismate pathway enzymes, the wild-type strain 13D pEV 
produced 2.8 ± 0.4 g/L of ethanol and had a maximum accumulation of 164.8 ± 13.3 mg/L of 
acetate. The deletion of the DAHP synthases (aro3 and aro4) in strain K34 pEV doubled the 
production of ethanol at 5.6 ± 0.3 g/L (Figure 16A). However, the amount of acetate 
accumulated by the strain was comparable to the amount accumulated by 13D pEV (Figure 
16B). Deletion of the Aro1 protein did not significantly change the ethanol production of the 















Figure 16. Comparison of ethanol and acetate production by strains 13D, K34, K341, 
K34M and K34A1Cln2. They are represented by (   ),(    ),  (   ), ( x ) and (   ) respectively. A) 
Ethanol production in strains expressing pEV plasmid representing the basal ethanol 
production in these strains. B) Acetate production in strains expressing pEV plasmid 
representing the basal ethanol production in these strains. C) Ethanol production in strains 
expressing p4BD plasmid that deregulates the chorismate pathway. D) Acetate production 
in strains expressing p4BD plasmid that deregulates the chorismate pathway. E) Ethanol 
production in strains expressing p6g plasmid that deregulates the chorismate pathway and 
expresses the heterologous cis, cis-muconic acid producing pathway D) Acetate production 
in strains expressing the proteins encoded by the p6g plasmid that deregulate the 
chorismate pathway and expresses the heterologous cis, cis-muconic acid producing 
pathway. All errors bars represent standard deviation of biological triplicates.  





accumulation in strain K341 pEV reached 431.4 ± 36.9 mg/L, which is a 2.5-fold increase as 
compared to acetate accumulation in strain13D pEV. Similarly, modifying the Aro1 shikimate 
dehydrogenase domain and decreasing the abundance of the Aro1 drastically changed the 
accumulation profiles of ethanol and acetate. K34M pEV produced 6.7 ± 0.7 g/L of ethanol and 
852.6 ± 45.6 mg/L of acetate, which is a 4-fold increase in acetate accumulation as compared to 
strains K341 pEV and K34 pEV. Similarly, K34A1Cln2 pEV also accumulated large amounts of 
acetate and ethanol, 2057.8 ± 153.3 mg/L and 8.9 ± 1.1 g/L respectively. This represents a 3-
fold increase in ethanol production and a 12-fold increase in acetate production as compared to 
13D pEV. This implies that modulation of the Aro1 node has significant effects on cellular 
metabolism and direction of carbon in the cell. 
Expression of the Aro4fbr, AroB and AroD (p4BD), which expresses a feed-back inhibition 
resistant Aro4 mutant, AroB and AroD, significantly affects ethanol production and acetate 
accumulation in the strains. Strain 13D p4BD has a maximum accumulation of 3.2 ± 0.1 g/L of 
ethanol (Figure 16C) and 343.5 ± 10.3 mg/L of acetate (Figure 16D) after 120 hours of 
fermentation. This is a modest increase in accumulation as compared to 13D pEV. Strain K34 
p4BD produces similar amounts of ethanol but more acetate as compared to K34 pEV at 3 ± 0.2 
g/L and 617.5 ± 20.8 mg/L respectively. Complete deletion of the Aro1 protein and over-
expression of the chorismate pathway had a drastic effect on ethanol and acetate production in 
the culture. K341 p4BD produced 6.6 ± 0.5 g/L of ethanol and accumulated 910.5 ± 43.5 mg/L of 
acetate. This is a 2-fold increase in ethanol production as compared to 13D p4BD and a 3-fold 
increase in acetate accumulation. The same trend is also seen in strain K34M p4BD. K34M p4BD 
had a maximum ethanol production of 7 ± 0.2 g/L representing a 2-fold increase as compared 
to 13D p4BD. Similarly, K34M p4BD also accumulated 918.2 ± 33.4 mg/L of acetate representing 
a 3-fold increase as compared to the acetate accumulation in 13D p4BD. Changing the 
abundance of Aro1 and overexpressing the chorismate pathway also has similar effects on 
ethanol and acetate production. Strain K34A1Cln2 p4BD has a maximum production of 9.2 ± 0.4 
g/L of ethanol and accumulates 1972.9 ± 194.6 mg/L of acetate. This is a 3-fold increase in 
ethanol production and 5.6-fold increase in acetate accumulation as compared to 13D p4BD. 





the cell. The over-expression of the chorismate pathway enzymes only exacerbates this 
phenotype, hinting at a possible metabolic bottleneck or redox imbalance. 
Expression of the heterologous pathway in these strains decreased the overall ethanol 
production and acetate accumulation as compared to simply over-expressing the chorismate 
pathway enzymes (Figure 16 E& 16F). The relative production and accumulation profiles of the 
different strains expressing the p6g plasmid are similar to those of the strains harboring the 
p4BD plasmid; just the total amounts produced are lower. This could be due to the lower 
accumulation of biomass in these strains or more carbon being pulled into the heterologous 
pathway and not into the cells native carbon sinks.  
These observations demonstrate that the chorismate pathway is essential in yeast’s central 
metabolism and any modulation of the Aro1 protein or over-expression of the chorismate 
pathway can drastically change the flow of carbon through the cell’s metabolism.  
3.7 Exploring the Effect of Two-step Fermentation of K341 on CCM and PCA 
Production 
 
In a recent publication Horwitz et al. attempted to produce CCM in S.cerevisiae using a Δaro1 
strain77. This study drew heavily from the work Curran et al.69 did to optimize CCM production 
in S. cerevisiae. Following a similar methodology, one copy of aroF, aroB, aroD, aroZ and catA 
and 6 copies of aroY were integrated into the aro1-coding region. This created a strain that was 
deficient in Aro1 functionality but expressed the heterologous CCM pathway. As the deletion of 
Aro1 functionality resulted in a strain that was deficient in aromatic amino acids and molecules, 
it could not grow in minimal production media. No effort was made to evolutionarily adapt the 
strain to accept minimal quantities of fed aromatic amino acids. Instead, the inability of the 
strain to create biomass in minimal media was used as a metabolic switch to control CCM 
production. The strain was first grown in 96-well shake plates in rich YPD media for 48 hours to 
accumulate biomass, and then the cells were transferred to minimal media containing 40 g/L of 
sucrose as a carbon source. As the cells were unable to replicate in the minimal media, all the 





of 2.7 g/L of PCA. This is highest reported accumulation of a heterologous aromatic molecule 
reported in literature demonstrating the success of the two-step fermentation process. There 
was an uncharacterized mutation or modification in the AroY protein that rendered it non-
functional and unable to convert any of the accumulated PCA into catechol and subsequently 
muconic acid. The functionality of CatA was determined by feeding the strain with 1 g/L of 
catechol resulting in a quantifiable but unreported amount of muconic acid.  
This two-step fermentation process was tested with the Aro1-deficient K341 strain. K341 lacks 
DAHP synthase functionality and the entirety of Aro1’s functionality. Additionally, this strain 
was evolutionarily adapted to be able to grow in minimal media with small amounts of 
aromatic molecule supplementation. A 6-gene plasmid expressing one copy each of Aro4K229L, 
AroB, AroD, AroY, AroZ and Hqd2 was expressed in this strain to provide carbon flux into the 
CCM pathway. This strain was then grown under similar conditions as the strain in Horwitz et al. 
After 48 hours in rich YPD media, the cells were transferred to 25 ml of minimal media 
containing 40 g/L glucose as a carbon source for 72 hours. The biomass accumulation of the 
cells stayed constant and started to decrease at the end of the fermentation as expected 
(Figure 17A). All the glucose was consumed in 24 hours. There was an accumulation of 2.7 ± 0.1 
g/L of acetate and a maximum accumulation of 7.6 ± 0.6 g/L of ethanol, which was 
subsequently consumed by the strain (Figure 17D). Additionally, accumulation of 32.2 ± 4.7 
mg/L of native precursor DHS was measured (Figure 17C). There was a large amount of carbon 
that was fed into the heterologous pathway resulting in an accumulation of 2.2 ± 0.2 g/L of PCA 
(Figure 17B). This is less than the amount of PCA accumulated by the strain in Horwitz et al. 
study. However, K341 p6g had a functional CCM pathway and was able to accumulate 0.95 ± 
0.1 mg/L of catechol and 14.56 ± 0.88 mg/L of CCM (Figure 17C). K341 p6g did not accumulate 
as much PCA as the strain created by Horwitz et al., however it was cultured under different 



















Figure 17. Comparison of growth and metabolite accumulation by K341p6g in a two-step 
fermentation process. The strain was grown in 25ml YPD for 48 hours and the cell pellet 
was collected and washed and then suspended in 25ml of YNB + 4% Glucose. The dotted 
line represents the time at which the growth conditions of the culture was switched A) 
Growth profile (  ) and glucose consumption (  ) of K341p6g. After the cells were suspended 
in minimal growth media, all the glucose was rapidly consumed without any increase in 
biomass. B) Accumulation of Protocatechuic acid (PCA). Upon culturing in the minimal 
growth media there was a rapid production and accumulation of PCA C) Accumulation of 3-
dehydroshikimate (DHS), Catechol and cis,cis-muconic acid (CCM) as represented by (  ),      
(  ) and (  ) respectively. D) Accumulation of ethanol (  ) and acetate (  ) in the culture. There 
was a maximum production of 7.60 ± 0.61 g/L of ethanol and 2.74 ± 0.03 g/L of acetate. 









The two-step fermentation method has been demonstrated as an efficient and practical 
method of controlling the production of heterologous products in this system. However, there 
is still a significant metabolic block in the lower parts of the CCM pathway. This is evidenced by 
the large accumulation of PCA in most of the CCM producing strains contrasted by the relatively 
poor accumulation of catechol and CCM.  
3.8 Effect of Oxygenation on PCA, Catechol and CCM Production 
 
The relatively low accumulations of CCM and catechol were addressed and ameliorated in the 
study published by Curran et al.69. The poor flux through the AroY enzyme that catalyzed the 
conversion of PCA to catechol was identified as the major problem and expressing more copies 
of the gene demonstrated an increase the titer of CCM to an impressive 141 mg/L. However, 
increasing the number of copies of a gene that are expressed, however successful, can have a 
limited effect on ameliorating a metabolic blockage as demonstrated by the accumulation of 
≈300 mg/L of PCA in the high CCM producing strain. Thus there is still a significant bottleneck 
present in this system.  
One cause of the severe restriction of the CCM pathway after PCA could be due to the 
oxygenation conditions of the culture. It has been previously demonstrated that the PCAD, 
AroY, is oxygen inhibited in its native functionality67. This is contrasted to the functionality of 
the CDO, Hqd2, which performs an oxygen-dependent ring opening step. Thus, it would seem 
that the last two steps of the CCM pathway have opposing oxygenation requirements. The 
conversion of PCA to catechol would have to be performed anaerobically and the conversion of 
catechol to CCM would have to be in aerobic conditions. Weber et al.67, had identified a 
previously published but uncharacterized isoform of AroY with the accession number 
AB479384.1 that was reported to not be oxygen-inhibited. This protein was able to convert 80% 
of the supplemented PCA to catechol. However, AB479384.1 was reclassified in 2013 to 
AB479384.2 and the amino acid sequence of this protein is identical to all the known PCAD 





in this study. As a large accumulation of PCA was demonstrated by both the latter studies with 
minimal catechol production, it is safe to assume that the PCAD, AroY, is still oxygen inhibited.  
To investigate this problem, it was decided to culture a CCM producing strain in a two-step 
fermentation with differing oxygen concentrations. Wild-type 13D S. cerevisiae was 
transformed with a plasmid, pDAC, which expresses a single copy of AroZ, AroY and Hqd2. This 
strain was then grown aerobically for 36 hours to accumulate biomass. Then 1g/L of glucose 
was added to the culture media, nitrogen gas was used to fill the headspace and the flasks were 
capped to promote anaerobic growth. After 48 hours of fermentation the caps were removed 
and the cultures were allowed to grow aerobically.  Their growth profiles and metabolite 
accumulation was compared to strains that were treated equally but were left uncapped to 
promote aerobic growth throughout the process. The uncapped cells accumulated more 
biomass than the capped cells during the period of capping, however, once the caps were 
removed the capped strains rapidly began to accumulate biomass and close the gap between 
the strains (Figure 18A). The capped strains also accumulated ethanol at a slower rate than the 
uncapped strain. (Figure 18A) The accumulation of shikimate was similar between the two 
strains (Figure 18 B). The uncapped and capped strains both accumulated PCA at low 
concentrations, 2.8 ± 0.4 mg/L and 2.2 ± 0.1 mg/L respectively, before the capping. At 96 hours 
of fermentation after the strains were capped, the PCA accumulation decreased to 0.9 ± 0.07 
mg/L in the capped strains as compared to an accumulation of 2.2 ± 0.1 mg/L in the uncapped 
strains (Figure 18C). This implies that the lack of oxygen in the culture media promoted the 
consumption of PCA. After the cultures were uncapped the PCA accumulation increased to 1.6 
± 0.1 mg/L. The opposite effect is seen in the accumulation of catechol between the strains.  
After 36 hours of fermentation, both the uncapped and capped strains had accumulated similar 
amounts of catechol, at 0.65 ± 0.05 mg/L and 0.58 ± 0.04 mg/L respectively. After 48 hours of 
oxygen limited growth, the capped strain had accumulated 1.06 ± 0.04 mg/L of catechol and 
the uncapped strain had accumulated 0.61 ± 0.06 mg/L of catechol. However, after being 
returned to aerobic growth the uncapped strain decreased its accumulation of catechol to 0.69 
± 0.14 mg/L, presumably converting it to CCM (Figure 18D). The CCM accumulation was also 















Figure 18. Comparison of growth and metabolite accumulation by 13DpDAC in an 
aerobic and anaerobic fermentation process. The strains that were grown aerobically are 
represented by (  ) and the strains that were grown aerobically for 48 hours are 
represented  by (  ). A) Growth profiles and ethanol production (secondary axis) of the 
strains. The ethanol production is represented by the dashed lines. B) Shikimate 
accumulation compared between the two growth conditions. C) Protocatechuic acid 
accumulation between the two strains with different growth conditions. D) Catechol 
accumulation between the two strains with different growth conditions. E) cis,cis-
muconic acid accumulation between the two strains with different growth conditions. All 







At 36 hours of aerobic growth both the capped and uncapped strains had accumulated similar 
amounts of CCM, at 0.21 ± 0.03 mg/L and 0.24 ± 0.01 mg/L respectively. During the 48-hour 
oxygen-limited fermentation period the accumulation of CCM in the capped strain remained 
constant while the CCM accumulation in the uncapped strain increased to 0.514 ± 0.02 mg/L. 
Once the strains were allowed to grow aerobically again, the accumulation of CCM in the 
capped strain increased to 0.56 ± 0.12 mg/L at 120 hours, comparable to the final accumulation 
of 0.65 ± 0.08 mg/L in the uncapped strain (Figure 18E).  
Thus, there are demonstrable effects of oxygen on the flux through the CCM heterologous 
pathway that need more investigation.  
4. DISCUSSION  
 
The production of adipic acid in S. cerevisiae would be economically, environmentally and 
sustainably beneficial. However, in order to have a large enough biological production system, 
the yields of adipic acid must be increased.  
The yields of adipic acid are directly proportional to the yields of its precursor cis,cis-muconic 
acid. The production of CCM is dependent on four factors: removal of feed-back inhibition in 
the chorismate pathway; increasing the flux through the AroB and AroD bottleneck; the amount 
of DHS being converted into native aromatic molecules; and the flux through the CCM 
heterologous pathway. 
 Curran et al.69 optimized the heterologous pathway to increase the flux through the rate-
limiting step, the conversion of PCA to catechol, resulting in a 90-fold increase in CCM yield. The 
amount of carbon entering the chorismate pathway was also increased by balancing the levels 
of precursors E4P and PEP and removing the feedback inhibition in the chorismate pathway. 
Increasing the flux through the AroB and AroD node was achieved by Weber et al67. by over-
expressing the E. coli cognate enzymes. However, modulating the loss of DHS into native 





Removing the feedback inhibition in the chorismate pathway and over-expressing AroB and 
AroD resulted in a strain with sufficiently high carbon accumulation in the chorismate pathway 
to try and channel it to a heterologous pathway. The K34 p4BD strain accumulated ≈ 360 mg/L 
of shikimate, which represents about 2% of the carbon fed to the cells. Using K34 as a base 
strain three different channeling strategies were explored. The aro1 deletion completely 
removed all shikimate production from the cell. However, this strategy had two negative 
consequences. Firstly, the strain is non-viable in minimal production media and had to be 
supplemented with aromatic molecules, which can get expensive in large scale fermentations. 
Secondly, removing Aro1 functionality also removes the native AroB and AroD functionality, 
which decreases the flux going through the chorismate pathway and into the heterologous 
pathway. This decrease in carbon flux could be the reason why strain K341 p6g did not 
accumulate as much PCA as K34 p6g, even with no shikimate production. Additionally, there 
was a large amount of DHS accumulated by strain K341 p6g as compared to the DHS 
accumulation in K34 p4BD or 13D p6g which points to inefficient carbon channeling. This large 
DHS accumulation was not seen in any of the other CCM producing strains and could be strain 
specific. It could point to some unknown regulation of the chorismate pathway or poor carbon 
utilization by the CCM pathway.  
The mutation of the Aro1 shikimate dehydrogenase domain has more desirable effects on PCA 
accumulation. The mutation dramatically disrupted the conversion of DHS to shikimate. Strain 
K34M p4BD accumulated double the amount of DHS as strain K341 p4BD and almost no 
shikimate. In strain K34M p6g this channeling strategy was successful in diverting carbon flux 
from the native pathway. In 120 hours of fermentation, K34M p6g accumulated only ≈9 mg/L of 
shikimate while it accumulated ≈413 mg/L of PCA. This represents a 9-fold decrease in 
shikimate accumulation as compared to strain K34 p6g. It also represents a 72% increase in PCA 
accumulation as compared to K34 p6g and a 163% increase as compared to 13D p6g.  
The third and final optimization strategy involved decreasing the abundance of Aro1 in order to 
decrease the conversion of DHS to shikimate. Although, strain K34A1Cln2 p4BD was successful 





PCA accumulated by strain K34A1Cln2 p6g was similar to the amount accumulated by K34 p6g. 
This tells us that although the DHS accumulation optimization strategy worked, there was a 
decrease in carbon flux into the heterologous pathway. This is similar to K341 p6g and has the 
same root cause. Decreasing the abundance of Aro1 also decreases the native functionality of 
AroB and AroD in the strain. This led to a decrease in the amount of DHS that was produced. 
Thus, we can conclude that the mutation in the shikimate dehydrogenase domain of Aro1 is the 
most effective way to reduce the amount of carbon going into the native aromatic pathway and 
channel it into the CCM pathway.  
The two-step fermentation with different carbon sources as demonstrated by Horwitz et al.91 is 
a practical way to use the aromatic molecule auxotrophy created by the deletion of aro1 to our 
advantage. However, this method first grows the cells in rich media for 48 hours and 
subsequently pellets and washes the cells to remove all traces of rich media and finally 
suspends them in minimal production media with high amounts of carbon. These manipulations 
are possible in small bench-scale experiments but would be impractical and prohibitively 
expensive in large-scale fermentations. Additionally, there were other concerns with this 
strategy using strain K341. The strain used by Horwitz et al. accumulated 2.7 g/L of PCA while 
K341 p6g only accumulated 2.2 g/L. This could be explained by a number of reasons. Firstly, the 
Horwitz et al. strain was fermented in 4% sucrose while K341 p6g was fermented in 4% glucose 
as a carbon source. This changes the way carbon enters the glycolytic cycle in yeast. As sucrose 
is broken down to glucose and fructose, which are subsequently phosphorylated once they 
enter the cell, there is an abundance of glucose-6-phosphate and fructose-6-phosphate in the 
cell. Both these molecules are consumed in the glycolytic pathway; however, glucose-6-
phosphate is also consumed by the pentose phosphate pathway that ultimately produces E4P. 
It is possible that feeding the cells both fructose and glucose channels more carbon into the 
pentose phosphate pathway ultimately producing more E4P. This would balance the amount of 
PEP and E4P produced in the cells, which was a rate-limiting step for the chorismate pathway 
identified by Curran et al69. Additionally, strain K341 underwent evolutionary adaptation to 
grow on the least amount of aromatic molecule supplementation. This adaptation could have 





uncharacterized pathways. This would decrease the amount of carbon being shunted into the 
heterologous pathway leading to a comparatively lower accumulation of PCA. Therefore, 
evolutionarily adapting the strain, although necessary for viable growth, could have 
inadvertently resulted in lower yields of heterologous aromatic molecules. Though, the 
adaptation to much lower amounts of aromatic molecule supplementation opens the question 
as to what functional changes the evolutionary adaptation caused in the cells. RNAseq and 
metabolomics studies would have to be conducted on K341 cells to determine the exact 
biochemical nature of the adaptation to pinpoint the mechanism of aromatic molecule 
production in the Aro1 deficient strain.  
The low titer of the actual desired molecule, CCM, also has to be examined. Even though there 
was a significant accumulation of PCA in the cells, there was very little catechol and CCM 
produced (Table 4). This could be because the flux through the AroY protein was really poor. 
However, Curran et al. also used one copy of the PCAD and CDO in their first strain and 
accumulated 15 mg/L of CCM. This would point to some unknown error in the AroY or Hqd2 
protein used in this study. However, as all the constructs were sequence verified for accuracy 
there has to be another problem. Another obvious problem could be the oxygen-inhibition of 
PCAD. But, as Curran et al. also fermented their strain in aerobic conditions, it does not offer a 
satisfactory explanation. The difference in the background strains used in the two studies could 
be a reason for the low accumulation of catechol and CCM. Curran et al. used BY4741 as their 
background strain, while Horwitz et al., Weber et al. and this study used CEN.PK. BY4741 and 
CEN.PK are not isogenic and have many uncharacterized nucleotide differences. CEN.PK has a 
4.5% difference in coding regions as compared to S288C, the parent strain of BY4741117. These 
could have an uncharacterized effect on the production of aromatic molecules. However, as the 
differences in the strains are uncharacterized there are no definitive reasons.  
The oxygenation requirements of the heterologous pathway were also examined in this study. 
This was done with a wild-type strain expressing the pDAC plasmid and not the high producing 
K34M p6g strain.  As described earlier, the absence of oxygen in the anaerobic cultures led to a 





accumulation of CCM remained constant throughout the anaerobic phase. This is consistent 




























the cultures were grown aerobically again, the accumulation of catechol decreased and the 
accumulation of CCM increased. This tells us that any CCM producing strain needs to be 
fermented first in anaerobic conditions to promote the conversion of PCA to catechol, and 
subsequently in aerobic conditions to convert all the accumulated catechol to CCM. Otherwise, 
AroY could be engineered to be resistant to oxygen inhibition using directed or random 
mutagenesis techniques which would allow a simpler fermentation process.  
In addition to precursor flux and oxygenation requirements the loss of carbon into native 
carbon sinks such as ethanol and acetate was also examined in this study. It was observed that 
any modulation to Aro1 drastically increases ethanol and acetate production in the cell. This 
can be explained by accumulation of phosphoenolpyruvate (PEP) because of the chorismate 
pathway. The accumulation of PEP as a result of erythrose-4-phosphate (E4P) being limited by 
the stoichiometric imbalance between the glycolytic pathway and the pentose phosphate 
pathway has been reported earlier9,69. So forcing large amounts of carbon into the chorismate 
pathway without balancing the stoichiometric levels of E4P and PEP, results in an accumulation 
of PEP, which is subsequently converted into ethanol and acetate. Additionally, two molecules 
of PEP are used in the shikimate pathway; one to make DAHP and the other to make 5-
enolpyruvl-shikimate-3-phosphate (5-ESP). Removing or drastically reducing the 5-ESP 
production by disrupting the functionality or abundance of the shikimate dehydrogenase 
functionality leads to half the PEP original being used in the pathway to accumulate, which in 
turn would be converted to ethanol and acetate. Surprisingly, decreasing the abundance of 
Aro1 has a much more pronounced effect on acetate and ethanol production as compared to 
mutating aro1 or deletion of the entire gene. However, it is observed that even though large 
amounts of ethanol are produced in the cell, it is all subsequently consumed during the 
stationary phase of the fermentation. On the other hand, acetate is mostly produced in the 
stationary phase and then accumulates in the cell. Thus, to increase the amount of CCM 
produced the amount of acetate accumulated must be reduced. This can be done by reducing 
the conversion of PEP to pyruvate, which would limit the production of acetate. The enzyme 
that converts PEP to pyruvate, Cdc19, is an essential enzyme so it cannot be removed entirely 





functionality. The Cdc19 T21E mutant has been characterized to mimic the phosphorylated 
state of Cdc19 and reduce its functionality, causing an accumulation of PEP118. This modification 
would decrease the amount of acetate and ethanol produced limiting the siphoning of carbon 
towards undesired native yeast metabolism.  
Putting it all together, in this study three important observations were made about the 
production process of CCM, which if addressed, could lead to strains that could be used for 
industrial production. Firstly, mutating the shikimate dehydrogenase domain of Aro1 causes 
more carbon to be diverted into the heterologous pathway by preventing the conversion of 
DHS to shikimate. Secondly, modulating the Aro1 node has a drastic effect on carbon flow 
throughout the cell as a large production and accumulation of acetate and ethanol are 
observed. And finally, there are opposing oxygen requirements in the CCM producing pathway 
which could be one of the causes of a poorly functioning PCAD enzyme.  
Thus, to create a strain that produces a large amount of CCM, I would propose the following 
modifications. Over-expressing the transketolase, Tkl1, would balance the amounts of PEP and 
E4P in the cell. Deleting the native DAHP synthases and expressing the feedback inhibition 
resistant Aro4K229L mutant that has been previously characterized should remove the feedback 
inhibition of the chorismate pathway. The E. coli AroB, and AroD should also be over-expressed 
to complement the native Aro1 functionality. This would, essentially, open the floodgates for 
the chorismate pathway, forcing a large amount of carbon into it. Next, the shikimate 
dehydrogenase domain should be mutated to create Aro1K1370E, which would minimize the 
conversion of DHS to shikimate, leading to an increase in DHS accumulation. The heterologous 
pathway as published by Curran et al.69, composing of 2-3 copies of aroZ, 6-7 copies of aroY and 
2-3 copies of hqd2, should be added to this strain. Subsequently, this strain should be cultured 
with large amounts of a carbon source in a two-step process starting with a period of anaerobic 








This study revealed multiple ways to improve the yield of heterologously produced CCM in S. 
cerevisiae. The Aro1 node of the chorismate pathway was successfully modulated to change 
how the carbon flows through the cell. Carbon was successfully diverted from native aromatic 
molecule synthesis into the heterologous pathway. Additionally, different fermentation 
processes were explored with the aim of increasing CCM titers. Two-step fermentations with 
anaerobic followed by aerobic cultivation was found to reduce the accumulation of 
intermediated in the CCM pathway and accumulate more CCM. And finally, effects of 
modulating Aro1 functionality on ethanol and acetate production in the cell were characterized. 
This can all be amalgamated into one strain that will be used to produce CCM on an industrial 
scale so we can wean ourselves off our dependency on non-renewable and polluting sources of 
raw production materials.  
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